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ABSTRACT
Campylobacter jejuni is the leading cause o f gastroenteritis.Infections are
endemic in developing countries and the emergence o f antibiotic resistant isolates in
developed countries underline the requirement for new therapeutic targets.
C. jejuni possesses a capsule, which is important in conferring virulence. The
capsule o f some C. jejuni species contains unusual modified heptoses. The genes
cjl427c, cj1428c and cj1430c putatively encode enzymes involved in modifying
heptose. We hypothesize that modified heptoses play a role in virulence in hostpathogen interactions, and have constructed and phenotypically characterized a
.X ■'
cjl427::CAT disruption mutant to complete our panel o f mutants. Complementation of
the mutants was conducted to ensure that the observed phenotypes are gene specific.
The capsular composition o f our mutants has been elucidated via NMR, allowing
us to correlate capsular structure and the observed phenotypes.
This work will lead to a better understanding o f the role o f modified heptoses in
host-pathogen interactions.
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CHAPTER 1 - INTRODUCTION
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1.1

Historical perspective
Food is a necessity o f life. In the past, mankind secured food through hunting and

gathering and agriculture. Today, most of the food consumed by the world is supplied by
the food industry; the use of intensive farming and industrial agriculture techniques
allows food to be produced on a large scale to meet the increasing needs and demands of
mankind.
Due to the large amounts of food being produced in today’s society, there is a
need for food preservation; a process of treating and handling food in a manner that stops
or slows down the spoilage o f food to allow for longer storage. Preservation can take a
number of different forms including sugaring and canning (i.e. jams), boiling,
dehydration, etc. These methods all accomplish the same goal: to prevent the growth of
bacteria, yeasts, fungi and other microorganisms.

1.2

Foodborne and waterborne diseases
Foodbome disease is the result o f ingesting food that has been contaminated by

pathogenic bacteria, viruses, or parasites, in addition, foodbome disease can be caused by
ingesting foods contaminated by poisonous chemicals and/or other harmful substances
(2). The global burden of foodbome illness is currently unknown, but the World Flealth
Organization (WHO) has estimated that in 2005, 1.8 million people died from diarrheal
diseases, largely attributable to contaminated food and drinking water (121). This
problem is not restricted to developing countries; foodbome illnesses also occur in
developed countries. The Centers for Disease Control and Prevention (CDC) estimates
that in the United States alone, 76 million foodborne illnesses occurs each year, resulting
in 325,000 hospitalizations and over 5000 deaths (125).
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More than 200 microbial, chemical or physical agents can cause illness when
ingested (6). Within the last 20 years, foodborne diseases caused by bacteria, parasites,
viruses and prions have gained significant public attention (121). Before 1960, the major
causes of foodborne illnesses included Salmonella spp., Shigella spp., Clostridium
botulinum and Staphylococcus aureus. During the 1960s, Clostridium perfringens and
Bacillus cereus were added, and in the 1970s, rotavirus and norovirus. In the 1980s and
1990s, many new pathogens were recognized including Campylobacter, Yersinia,
Listeria

monocytogenes,

new

strains

of Escherichia

coli

such

as

0157:H7,

Cryptosporidia and Cyclospora. to name a few (121).
Several factors of modern society contribute to the occurrence of foodborne
illnesses. These include, but are not limited to: large scale production and wide
distribution of food; globalization of the food supply; eating outside the home; the
emergence o f new pathogens; and a growing population of at risk consumers.
Improvements in the safety o f food have been driven largely by public demand in
response to disease outbreaks. As a result, international standards and legislation have
been implemented, decreasing worldwide diarrheal incidences as reported by the WHO
(5).
Foodstuffs are not the only source for potential illness; pathogens can also
contaminate large water supplies. As o f 2006, the CDC estimated that a staggering 1.1
billion people lack access to clean water (1). The burden o f unpotable water and poor
sanitation and hygienic conditions is mostly concentrated in developing countries,
particularly amongst children (4). However, waterborne diseases also occur in developed
countries. In past cases of waterborne illnesses, often preceding the pandemic is a period
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of heavy rainfall and/or melting snow. The increase in precipitation often leads to run off
o f surface water into the local water supply. Problems arise when surface run off mixes
with animal feces, particularly from farms, resulting in potential contamination of the
water supply. Changes in weather climate are thus an important factor to consider when
attempting to reduce the impact of waterborne diseases. In addition, it must also be taken
into consideration the method in which pathogens are able to move from source to the
host. This includes how pathogens may contaminate source water, evade water treatment,
etc.
It is clear that despite efforts from scientists, governments and the food industry,
foodbome and waterborne illnesses continue to be a major public health problem
worldwide, with implications for both the citizens and the economy of nations. Thus,
further research must be conducted to prevent and control the spread o f the causative
agents of foodbome and waterborne illnesses.

1.3

Campylobacter jejuni
Theodor Escherich first noted in 1886 non-culturable, spiral shaped bacteria in

stool specimens and the large intestinal mucous associated with diarrhea in neonates and
kittens. Later, various publications appeared describing the occurrence of “spirilla”
shaped bacteria in “cholera-like” and “dysenteric-like” disease (91). These descriptions
were likely the first account of Campylobacter species. Notably, in 1938, a total of 357
prison inmates were infected by a “spirillum shaped bacteria” (104). It was not until 1963
that the genus was first described, and Campylobacter was not isolated until 1972 (119,
145) due to its fastidiousness.
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Campylobacteriae are Gram negative bacteria, approximately 0.5 to 8 pm in
length, and 0.2 - 0.5 pm wide. They possess a characteristic spiral, or corkscrewed shape
(148). Their ability to move rapidly in a corkscrew fashion is attributed to their uni- or
bipolar flagella (34, 92). Campylobacters are catalase and oxidase positive, and urease
negative. They are microaerophilic, requiring a nitrogen rich atmosphere with low
oxygen (5%) and high carbon dioxide (10%) (119). A growth temperature o f 42°C,
corresponding to the natural temperature of the avian gut, their natural host, allows for
optimal growth of Campylobacters, however, growth at 37°C is also tolerated. When
stressed, Campylobacters can change into a coccoid form; this form is called the “viable,
but non-culturable” form. This occurs when Campylobacters encounter environmental
stress such as nutrient starvation, osmotic shock and fluctuations in temperature and pH
(75). While in this state, the ability to culture Campylobacters is lost, even though the
microorganism is alive and metabolically active (127). There are many different
Campylobacter species, including C. jejuni, C. coli, C. upsaliensis, C. lari, C, concisus,
but approximately 90% of human infection is caused by C. jejuni, with C. coli accounting
for much o f the rest (30, 50).

1.3.1

C. jejuni pathogenesis
C. jejuni is a commensal bacteria in the intestinal tract o f birds and mammals,

including domestic chickens (178). Disease often arises from the consumption of
contaminated meat, particularly during food processing and preparation. In addition,
outbreaks of Campylobacter induced gastroenteritis, termed Campylobacteriosis, can be
contracted from drinking contaminated water. Most notably, in May of 2000, in the town
of Walkerton, Ontario, Canada, after several days of heavy rainfall, an outbreak of E. coli
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0157:H7 and Campylobacter occurred, resulting in the deaths o f seven people and
approximately 2500 more becoming ill (11). This outbreak was due to a combination of
contributing factors including heavy rainfall causing cattle manure from a neighbouring
farm to be washed into the water supply, and insufficient chlorination of the water supply.
The major role that Campylobacter played in this outbreak of water-borne disease was
largely ignored by the media and the public.
In developed countries, C. jejuni is a leading cause of acute gastroenteritis. With
an infectious dose of as low as 500-800 bacteria, C. jejuni can produce inflammatory,
sometimes bloody, diarrhea or dysentery like syndrome, and often is accompanied by
cramps, fever and pain. The organism colonizes the small intestine of the human host
early in infection and later moves to the colon, which is the target organ (17, 164).
Although C. jejuni is generally considered invasive, the level of invasion of intestinal
epithelial cells in vitro varies among strains (164). The incubation period that precedes
acute diarrhea is 2-5 days and although the disease is self-limiting and usually resolved
within one week, symptoms can persist for up to two weeks (178).
A long term consequence o f C. jejuni infection is Guillain-Barre Syndrome (GBS)
and its variant, Miller Fisher syndrome. GBS is considered an autoimmune reaction, and
causes acute ascending neuromuscular paralysis, characterized by rapidly evolving
symmetrical limb weakness, loss o f tendon reflexes, the absence of mild sensory signs
and autonomic dysfunctions (179). It is thought that the antibodies generated against the
bacterial lipooligosaccharide (LOS) cross react with host gangliosides, resulting in their
destruction (7, 179). Since the near eradication of poliomyelitis worldwide, GBS ranks as
the most frequent cause of acute paralysis; the annual incidence being one or two cases
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per 100 000 population (73). In 1982, Rhodes and Tattersfield (140) reported the first
case of a patient who developed GBS after C. jejuni associated enteritis. Since then, there
have been many reports of C. jejuni associated GBS cases. In Australia, 21 of 56 patients
with GBS had evidence of anti-Campylobacter antibodies, while controls had none,
showing a strong correlation between Campylobacter and subsequent GBS (79).
However, it remains difficult to absolutely associate C. jejuni with GBS because the
bacteria are usually eliminated from the body within 16 days o f infection and before the
onset of neurological symptoms, which normally begin 10 days to three weeks after the
onset of diarrhea (136). As Campylobacter is not routinely diagnosed in rural health
clinics, many Campylobacter-associated GBS cases may go unrecognized because by the
time symptoms present themselves, Campylobacter is no longer present (72, 111).
In addition to Campylobacter-associated GBS, acute bacterial enteritis has been
implicated as one o f the factors that may incite or exacerbate patients with inflammatory
bowel diseases (IBD), such as Crohn’s disease or ulcerative colitis. These diseases are T
cell-mediated and characterized by chronic, relapsing inflammation o f the intestinal tract
(80). IBD causes lifetime morbidity and in Canada alone, accounts for a financial burden
exceeding 1.8 billion dollars per year in economic loss (including greater than 700
million dollars in direct medical costs) (3). The mechanisms by which Campylobacter
causes inflammatory disorders in the bowel remain obscure. Evidence suggests that
Campylobacter disrupts intestinal epithelial structure and function and thereby permits
the translocation o f luminal material, including resident intestinal bacteria, into the
subepithelial compartment (74, 80, 99). The loss of intestinal epithelial barrier function
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and the subsequent failure to downregulate inflammation following intestinal epithelial
injury may lead to IBD (152).

1.3.1.1

C. jejuni associated invasion
To

establish an infection,

C. jejuni must bypass the mechanical

and

immunological barriers of the host gastrointestinal tract. The mucus layer of the GI
epithelium serves as the first layer of defense, but C. jejuni possesses several virulence
factors to circumvent this barrier (178). In particular, motility, combined with the spiral
shape, allows the bacteria to effectively “drill” through the mucus lining of the
gastrointestinal track (40). Genome sequencing analysis has also shown that the C. jejuni
genome encodes many o f the features found within the E. coli chemotaxis system (101,
131). C. jejuni displays motility towards amino acids that are found in high levels in the
chick gastrointestinal track and towards components of mucus (71).
The invasion of intestinal epithelial cells has been observed in patients and is
reproducible in cell lines in vitro (163), albeit at very low levels (39, 47, 100, 157). The
mechanisms that control invasion are not elucidated, but differences exist between
individual strains. It has become clear that microtubule polymerization is required for
maximal invasion; some strains also require microfdament polymerization (16, 70, 126).
This contrasts the actin-dependent mechanism of entry that is used by many other
bacteria.
Similar to the type III secretion system that is employed by Salmonella
typhimurium and Shigella flexneri, whereby effectors are delivered into the host cell, C.
jejuni also secretes proteins from the flagellar type III secretion system. This is a
requirement for maximal invasion of host epithelial cells (29). The proteins that are

9
synthesized and secreted by C. jejuni upon co-cultivation with epithelial cells are termed
Campylobacter invasion antigens (Cia) (96). Only a few C. jejuni secreted proteins have
been identified to date due to low levels of protein secretion under in vivo conditions (29).

1.3.1.2

Ability of C. jejuni to survive within macrophages
C. jejuni survives within murine macrophages (149). The role of monocytes and

macrophages in C. jejuni infection is unclear because results vary with different cell lines
or primary cells (178). Inflammatory cytokines such as NF-kB (nuclear factor kappa B)
and interleukin-ip are produced in the presence of C. jejuni; however, a significant
proportion o f monocytes also undergo apoptosis (168). C. jejuni is killed within 24 - 48
hours of infection by macrophages. Within 4 - 8

hours, a significant portion of the

bacteria turn into the non-culturable coccoid form when exposed to macrophages (174).
However, other groups have found that clinical isolates of C. jejuni survived for several
days inside the murine J774A.1 macrophage cell line (35, 67). Regardless o f the
contradictory data currently available, the consensus is that the differences observed in C.
jejuni interactions with macrophages are likely due to strain variation and the use of
different macrophage and/or macrophage cell lines.

1.3.2

C. jejuni virulence factors
Although C. jejuni is a commensal organism in mammals and birds, it has the

ability to cause illness in humans. Several virulence factors are expressed by C. jejuni,
which are discussed below.
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1.3.2.1

Glycosylated proteins
C. jejuni expresses two systems of protein glycosylation: O-linked glycosylation,

which modifies serine or threonine residues on flagellins, and iV-linked glycosylation,
which modifies asparagine residues on many secreted proteins (178).
0-linked protein glycosylation is involved in the glycosylation of C. jejuni
flagellins. The flagellins in strain 81-176, a human gastric isolate of C. jejuni, are
glycosylated with pseudaminic acid at up to 19 sites, accounting for approximately 10%
o f their observed mass (159). Meanwhile, the flagellin o f C. coli strain VC 167 is
modified with legionaminic acid, and the genes that encode the proteins that are involved
in synthesizing this glycan are shared by many strains of C. jejuni, with the exception of
the 81-176 strain (112). No consensus sequence has been identified for 0-linked
glycosylation; however, it is required for the proper assembly of the flagellar filament
(51). This suggests that O-linked glycosylation is required for the interactions of the
flagellin subunits with each other, or with another component of the flagellar apparatus.
Defects in 0-linked glycosylation result in loss o f motility, a decrease in adherence and
invasion o f host cells, and decreased virulence in ferrets (57).
Prior to the discovery in C. jejuni, the AMinked glycosylation pathway had only
been observed in eukaryotes and archaea. In C. jejuni, V-linked glycosylation is encoded
by the pgl (protein glycosylation) locus. Unlike other surface carbohydrates in C. jejuni,
such as lipooligosaccharide, capsular polysaccharide, and O-linked glycans, V-linked
glycans appear to be conserved in all C. jejuni strains that have been examined to date,
and exhibit very little potential for phase variation (158). This conservation implies that
V-linked glycosylation may have a fundamental role in C. jejuni physiology. The site for
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yV-linked glycosylation, unlike 0-linked glycosylation, has a consensus sequence: aspartic
acid/glutamic acid - X - asparagine - X - serine/threonine, where X can be any amino
acid except proline (98, 122). While this sequence is vital for glycosylation, there are
other factors, such as tertiary or quartemary structure that also play a role (122). The role
of TV-linked glycosylation in C. jejuni is not clear. Mutations in the pgl locus have effects
on multiple glycosylated proteins; this results in reduced adherence and invasion to
intestinal cells, loss of mouse and chick colonization, reduced protein activity to antisera,
and defects in natural competence (65, 78, 83, 88, 101, 123, 156).

1.3,2.2

Flagella
C. jejuni flagella and flagellar motility are vital for host colonization, virulence in

ferret models, protein secretion and host-cell invasion (178). The motility of C. jejuni
increases in highly viscous solutions and the speed has been reported to reach 75 pm per
second under these conditions (102). This motility may facilitate movement of C. jejuni
in and through the thick mucus lining o f the intestinal tract (40, 102). Black et al (17) fed
human volunteers mixtures of motile and non-motile phase variants and subsequently,
recovered only motile forms from stool samples. This was the first evidence that motility
was required for intestinal colonization.
The flagella consists of a major flagellin, FlaA, and a minor flagellin, FlaB, that
are highly homologous (55). The flaA gene is regulated by a a

promoter, while flaB is

regulated by a a 34 promoter (54). Mutations in flaA result in a severely truncated flagellar
filament, with a reduction in motility, while mutants in fla B , in contrast, have no
significant change in motility and produce a flagellar filament that appears normal (55,
124). Many strains of C. jejuni undergo phase variation in flagellin expression by slip
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strand mismatch repair (25, 64). The ability of C. jejuni to undergo changes in motility
and flagellar expression may be beneficial to the organism so that it can adapt to the
different environments it encounters within the host.
A connection between flagella and colonization has been established (157). While
motility was found to be important for colonization of epithelial cells, genomic studies
have also found that C. jejuni strains lack a specialized type III secretion system (46).
However, there are reports that flagella can function to secrete non-flagellar proteins that
may modulate virulence. Konkel et al showed that the secretion of at least eight proteins
into the supernatant occurs when C. jejuni was co-cultured with epithelial cells (96, 97,
143). The secretion of Cia proteins, but not their synthesis, was dependent on growth of C.
jejuni in the presence of INT407 intestinal cells (96, 97, 143). Thus far, only one Cia
protein, CiaB, has been identified. Mutation in ciaB results in full motility, but the
pathogen is unable to secrete any Cia proteins. Moreover, the mutant was reduced 50-fold
in invasion into epithelial cells compared with the parent strain (54, 96). This implies that
while motility is not essential for colonization and invasion of the intestinal epithelium,
an intact flagellar apparatus is required.

1.3.2.3

Adhesins
C. jejuni produces several adhesins to colonize intestinal epithelial cells. Many

microorganisms typically have surface appendages such as pili that facilitate adherence.
However, genome annotations of several C. jejuni strains do not show obvious pilus or
pilus-like open reading frames (43, 131). Despite the lack of pili, several proteins
contribute to C. jejuni adherence. CadF {Campylobacter adherence factor) binds
specifically to fibronectin, which is located basolaterally on epithelial cells (95, 116).
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CadF is required for maximal binding and invasion by C. jejuni in vitro, and cadF
mutants are greatly reduced in chick colonization compared with wild type (117). While
CadF is similar to the OmpA protein in E. coli in that it forms membrane channels, its
precise function has not been established (109). Another characterized adhesin is JlpA, a
surface exposed lipoprotein that is required for binding to Hep-2 epithelial cells (76).
Another lipoprotein, CapA, has also been implicated as important for C. jejuni adhesion
to Caco-2 cells, as CapA deficient mutants show decreased adherence, colonization and
persistence within them (8). Some putative C. jejuni adhesins are in the periplasm. Pebl
is an adhesin that is required to bind to HeLa cells (90, 133). However, the majority of
this adhesin is periplasmic and shares homology to periplasmic binding proteins of amino
acid transporters, binding to both aspartate and glutamate with high affinity (103, 132). In
addition, while Pebl does not localize to the inner or outer membrane, some must be
surface exposed in order for this protein to act as an adhesin. While it was suggested that
Pebl is anchored to the outer membrane, no evidence has been found, and instead, Pebl
was observed in culture supernatants, suggesting that the protein can be exported across
the outer membrane (103).

1.3.2.4

Lipooligosaccharide (LOS)
C. jejuni expresses low molecular weight outer membrane antigens known as

lipooligosaccharide (LOS). In many Gram negative bacteria, a set of repeating sugar
subunits, the O-chain, is attached to the core polysaccharide, and the entire structure is
termed lipopolysaccharide (LPS). However, much like in Neisseria and Haemophilus sp.,
the LOS of C. jejuni does not possess the long repeating O-antigen polysaccharide chains
characteristic of LPS. The pioneering structural work of LOS was done by Aspinall et al
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(118), and further refined by Szymanski et al (158). The LOS is anchored to the
membrane via lipid A; attached to the lipid A anchor is the core region o f the LOS. The
core can be subdivided into the outer core region, proximal to the O-specific chain, and
the lipid A proximal inner core region (141, 142). This subdivision exists because of the
different sugar composition of the two regions. The outer core consists o f hexoses and
hexosamines, specifically, galactose and N-acetyl galactosamine, while the inner core
consists of sugars such as two molecules of heptose and 3-deoxy-D-maw70-2-octulosonic
acid (Kdo) (118). The Kdo sugar serves as a link between the core oligosaccharide and
the lipid A component. Interestingly, C. jejuni is one of the few bacteria capable of
endogenous synthesis of sialic acid for incorporation into the galactose molecules present
in the outer core. The resulting sialylation gives rise to molecular mimicry of host
gangliosides, which can result in the development of autoimmune neuropathies such as
GBS and Miller Fisher syndrome (58).

1.3.2.5

Capsular polysaccharide (CPS)
Capsules are found on the surface o f many Gram positive and Gram negative

bacteria. Capsules are considered a virulence factor and can be potentially antigenic.
They can either be tightly associated or form a loose, gel-like matrix, and impart a great
deal of protection to the bacteria. These include protection from desiccation,
bacteriophages, and most hydrophobic toxic materials such as detergents. In addition,
capsules provide protection against the complement system by preventing C3 deposition
on the surface of the bacteria (166). Capsules also aid in bacteria adherence to surfaces.
Until recently, it was thought that C. jejuni strains produced both LOS and a high
molecular weight lipopolysaccharide (LPS) (86). C. jejuni CPS remained largely
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unnoticed until the sequencing of the ATCC 700819 genome where a large cluster of
genes with similarities to type II/I1I CPS transport genes from Enterobacteriaceae were
found (131). Mutations in these transport genes resulted in a loss of the high molecular
weight polysaccharide, as well as the loss of the ability to be typed in the Penner
serotyping scheme. A characteristic feature o f group II capsular polysaccharides is the
presence of a phospholipid anchor. Karlyshev et al showed that the high molecular
weight polysaccharide was susceptible to phospholipase treatment, thus confirming that
what originally was thought to be a high molecular weight LPS was actually a highly
variable capsular polysaccharide (CPS) (86).

1.3.2.6

Role of CPS in C. jejuni virulence
The CPS of C. jejuni is a virulence factor that is important for adherence to and

invasion of epithelial cells, chick colonization and virulence in a ferret model (13, 77). A
capsuleless KpsE mutant in strain ATCC 81116, isolated from a waterborne outbreak in
1982, showed decreased adherence and invasion in intestinal epithelial cells (12) while
similarly, a capsuleless KpsM mutant in strain ATCC 81-176 shows decreased invasion
of intestinal epithelial cells and decreased invasion in a ferret model (13). The same
mutant exhibits a decreased ability to colonize the chicken intestine (77). In addition, Keo
et al created capsuleless mutants in the invasive clinical isolates 84-25 and 84-19 strains
o f C. jejuni and found that they showed a significant increase in serum-dependent killing
compared to the wild type (89). These capsuleless mutants showed that CPS was critical
for serum resistance and was also responsible for subtle changes in surface charge.
However, it is not known whether differences in sugar composition o f the capsule among
different strains will affect virulence or whether phase variable modifications play a role.
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1.3.2.7

Group II and group III capsular groups
Much of the work related to CPS has been performed in E. coli, which has over

80 different capsular serotypes. These were originally divided into groups based on their
serological properties while later revisions incorporated genetic and biochemical criteria
(172). Since this original classification, there now exist four distinct groups (173). E. coli
group I and IV capsules share a common assembly system, and are fundamentally
different than the assembly system used for group II and III (172). While four main
capsular groups exist, the C. jejuni CPS shows high similarity to the E. coli group II and
III capsular groups (58, 131) and only these will be described below.

1.3.2.8

Capsular organization
The structural features of the repeating units of E. coli group II and III capsules

vary extensively; while some contain phosphate residues in their backbone, much like
Gram positive teichoic acids, some group II CPS resemble vertebrate glycoconjugates
(172).
The chromosomal locus for group II capsule has a generally conserved structure,
consisting of three regions (172). This organization is observed not only in E. coli but
also in other encapsulated bacteria such as Campylobacter, Haemophilus, Neisseria,
Pasteurella and Actinobacillus spp. (150). This conservation suggests a common origin
for the biosynthetic gene cluster in these species. In fact, Silver et al (150) showed that
homologues

of the E.

coli transporter from Actinobacillus pleuropneumoniae,

Haemophilus influenzae and Neisseria meningitidis complemented an export defective E.
coli mutant.
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Region 2 is known as the serotype specific central region, and encodes
glycosyltransferases as well as many unique sugar nucleotide synthetases required for the
production of capsule. As this region is serotype specific, the size and genetic content
will vary. In general, the size of region 2 corresponds to the complexity and the number
of repeat units of the capsular polysaccharide that is formed (172). Region 2 is flanked by
regions 1 and 3, which are generally conserved. Genes in these areas are involved in a
range o f activities including assembly and subsequent export of the polysaccharide via an
ATP-binding cassette (ABC) transporter, consisting of KpsM and KpsT.

1.3.2.9

Capsular biosynthesis
Biosynthesis and assembly o f capsular polysaccharides is a complex process.

Monosaccharides are the basic building blocks o f CPS; once the sugar molecules have
been synthesized by the bacterium or obtained from the environment, activation to the
sugar nucleotide form occurs. This activation step, whereby the sugars are activated to
XTP, XDP or XMP (where X indicates a nucleotide, adenosine, cytosine, thymine or
uridine,

and

TP,

DP

and

MP

indicate

the

triphosphate,

diphosphate

and

monophosphonucleotides, respectively), is required for the final polymerization step
catalyzed by glycosyltransferases that transfer the sugars to the correct acceptors (165).
Any modifications that occur to the sugar nucleotide precede the final polymerization.
After polymerization, the final polysaccharide can be exported to the cell surface where it
can be expressed. Each step of this biosynthetic pathway will be introduced below.
Initiation of group II capsular synthesis requires a membrane bound initiator
upon which the polysaccharide chain is elongated. The endogenous acceptor has been
described as phospholipid, phospholipid-linked 3-deoxy-D-mauuo-octulosonate (Kdo),
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“endogenous acceptor” protein, and undecaprenyl phosphate (23, 41, 160, 170). However,
to date, the exact nature o f the endogenous acceptor remains unknown.
Chain elongation is performed by glycosyltransferases that add additional sugar
units to the nascent capsular polysaccharide. This process occurs on the cytoplasmic side
of the membrane. A series of acetyl transferases and O-acetyl esterases have been
discovered that modify the nascent capsule polysaccharide or its precursors before or
during export (154). These modifications suggest that the synthetic components of group
II capsule biosynthesis may themselves be associated with the inner membrane,
interacting in a super-complex that Steenbergen et al have designated the sialisome (155).
The penultimate step to capsular biosynthesis is chain termination, but group II
CPS termination of chain polymerization is unsolved. In E. coli K l, the majority of the
capsular chains terminate with a maximum chain length of 160 - 230 residues, suggesting
an active process in size determination (134). A terminal residue on group II capsules
could potentially be overlooked in structural analyses (172). The other possibilities for
chain termination include the loss of affinity by the glycosyltransferases for the polymer
beyond a certain chain length, an abortive chain translocation process within the catalytic
site, or an allosteric effect that is mediated by other components of the capsular assembly
system (172).
The final step to express the complete capsular polysaccharide on the cell surface
is export. This process is driven by ABC transporters at the expense of ATP hydrolysis.
KpsM and KpsT were initially identified as the components of an ABC transporter on the
basis o f their sequences, and their identities were then confirmed by biochemical
approaches (150). KpsM is the integral inner-membrane transmembrane domain
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component, with six transmembrane helices, and KpsT is the cytoplasmic nucleotide
binding domain (172).
Two models of capsular export exist: post-synthetic or direct coupling (165). In
the former, as all group II and probably group III capsules bear a terminal reducing
phosphatidic acid moiety that anchors them to the outer membrane, this feature could
function as a recognition tag for export due to its commonality. In the latter model of
capsular export, the glycosyltransferases for polymerization are directed to the exporter
by affinity for accessory proteins, essentially coupling synthesis of the capsule to
polysaccharide export (165). There is growing evidence that the direct coupling model is
the correct model as Steenbergen et al showed that in the presence o f a depolymerase
(capable of cleaving capsular chains greater than or equal to 7 monomers in length),
cytoplasmic biosynthesis of the polysaccharide (both synthesis and subsequent export)
was protected from degradation. The depolymerase clips nascent chains prior to export;
in a post-synthetic transport model, the completed capsular chains would be eliminated
before their export, reducing or eliminating surface capsule expression. However, if
synthesis and export of the polysaccharide were intimate (as in a directed coupling export
model), the polysaccharide would be protected and the capsule expressed regardless of
the depolymerase. Results indicated that capsular synthesis was protected during
polymerization and export, supporting the directed coupling model (155).

1.3.2.10

The C. jejuni capsule and heptose biosynthesis genes

The CPS of C. jejuni strain ATCC 700819 is anchored to the outer membrane via
a dipalmitoyl-glycerophosphate phospholipid anchor (31). The C. jejuni ATCC 700819
capsular backbone contains a (3-D-ribose, p-D-Gal/NAc (N-acetylgalactosamine in a
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furanose conformation), a - D-G1c/?A 6 (A'gro) (a glucuronic acid with 2-amino-2deoxyglycerol on carbon 6), and a 3,6-0-meXhy\-D-glycero-a-L-gluco heptose as a sidebranch (153). When high-resolution magic-angle spinning nuclear magnetic resonance
(HR-MAS NMR) was used to examine intact C. jejuni cells, a large variation in capsular
structure was found (158). This included a 6-O-methyl group on the heptose, an Nethanolamine modification on glucuronic acid instead of the 2-amino-2-deoxyglycerol,
and a unique O-methyl phosphoramidate molecule on Gal/Nac that had not been
previously seen in any other bacteria (158). It is not known whether changes in sugar
composition of CPS plays a role in virulence or in interactions with bacteriophages. Other
strains of C. jejuni are known to possess modifications to heptose. For example, in the
81-176 strain, not only is the heptose in an altro conformation, but a dehydration also
occurs on carbon 6 (85).
Due to the side-branching nature of the modified heptose as well as the
phosphoramidate molecule in C. jejuni ATCC 700819, these molecules protrude into the
external environment, and become the outermost portion of the CPS that is exposed.
These moieties are likely important for bacterial/host interactions as well as pathogenicity
o f the organism. The enzymes that are involved in the synthesis o f these modified
heptoses are potential targets for therapeutic agents.
Most Gram negative bacteria contain a single heptose biosynthesis pathway in
their TOS or TPS biosynthesis loci, producing ADP-L-g/ycero-P-D-mrwno-heptose, a
precursor o f the core oligosaccharide (162). Interestingly, C. jejuni is an exception to this,
as some strains possess additional heptose biosynthesis genes involved in synthesizing
GDP-D-g/ycero-a-D-manno-heptose which are located within the capsular cluster of
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genes (82). The first step of the pathway to create the manno-heptose involves converting
D-sedoheptulose-7-phosphate to D-g/ycero-a-p-D-marmo-heptose-7-phosphate via the
isomerases GmhA and GmhA2 (Cj 1149c and Cj 1424c, respectively; Figure 1). The Dg/ycero-a-D-ma«no-heptose-l,7-bisphosphate is then formed via the kinase HddA
(Cj 1425c). GmhB (Cj 1152c), encoded from the LOS synthetic pathway, acts next to
remove

a

phosphate,

yielding

D-g/ycero-a-D-manno-heptose-l-phosphate.

HddC

(Cj 1423c) then acts to transfer a guanosine triphosphate (GTP) molecule, yielding GDPD-glycero-a-D-manno-hcplose (82). In some strains o f C. jejuni, this manno-heptose is
further modified before incorporation into the capsule via the heptosyltransferase HddD
(Cj 1431c). For instance, in ATCC 81-176, the conversion of heptose to deoxyheptose is
thought to occur, as a new gene, wcaG, was found within the genome (82). The WcaG
protein is a homologue of DmhA, known to be involved in conversion of heptose to
deoxyheptose in Yersinia pseudotuberculosis (24, 69, 130). Karlyshev et al report that
cjl427c, c/J428c and cj!430c are potential candidates for carbon 3,5 epimerase/carbon 4
reductases. These gene candidates are postulated to be involved in converting the Dglycero-a-D-manno-hcptose

to

GDP-6-OMe-D-g/yceroa-L-g/wco-heptose.

The

verification of the heptose biosynthetic pathway in C. jejuni ATCC 700819 via
mutagenesis studies is the main focus o f this thesis.
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Figure 1. Synthesis of D-g/ycero-a-L-g/wco-heptose and its subsequent incorporation
into the CPS.
The biosynthesis of GDP-6-OMe-D-g/ycero-a-L-g/wco-heptose in ATCC 700819 from
D-sedoheptulose-7-phosphate is shown. The genes gmhA, gmhA2, hddA, gmhB, and
hddC have known functions. The genes cj1426c, cj1427c, cj1428c, and cj1430c are
putatively thought to modify the heptose while cj 1431c is putatively thought to be a
heptosyltransferase.
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1.4

Rationale and hypothesis
Modified heptoses are relatively unique in bacteria. They have been found in the

CPS o f several strains of C. jejuni and C. coli, as well as the LPS o f Yersinia
pseudotuberculosis (28, 49, 69, 81, 82, 162). The CPS plays an important role in
pathogenesis, as a capsuleless mutant in C. jejuni ATCC 81-176 has reduced adherence
and invasion of intestinal epithelial cells as well as reduced virulence in a ferret diarrheal
model (13). It is not known whether specific components of the capsule, such as the
modified heptose and/or phosphoramidate molecule, play a role in pathogenesis. As these
molecules form side-branches away from the main capsular backbone, they are the
outermost exposed component of the capsule to the external environment, and may thus
play a role in pathogenesis. The capsular structure of C. jejuni ATCC 700819 was
elucidated and contains 6-0-methyl-D-g/ycero-a-L-g7wco-heptose (153). To achieve this
final conformation from the starting D-glycero-a-D-manno-hepXose, three epimerization
steps at carbons 3, 4 and 5 must occur in order to switch from the manno to the gluco
conformation, as well as to switch from the D to the L configuration. These epimerases
have not been identified. However, region 2 of the capsular cluster in C. jejuni ATCC
700819 contains three genes, cj1427c, cj1428c and cj1430c that are thought to putatively
perform these epimerizations on D-glycero-a-D-manno-heptose. The precise biochemical
functions of these enzymes are under investigation in our laboratory.
We believe that the enzymes encoded by cjl427c, cjl428c and cjl430c play
important roles in the synthesis of modified heptoses in the capsule of C. jejuni, and
that specific capsular components, such as modified heptoses, are important for
CPS function and the overall virulence of C. jejuni.
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1.5

Objectives

1) To determine the role of cjl427c, cjl428c and cjl430c in modified heptose
biosynthesis.
We have constructed cj!428::CAT and cjl430\:CAT insertional mutants, but
lacked a cj1427::CAT mutant. To complete our panel of mutants, and to determine the
function of these genes of interest, a cj1427::CAT mutant was created. The effects on
CPS production and composition o f these insertional mutants were also investigated.

2) To determine the effect on virulence due to subtle changes in the CPS of C. jejuni
Previous laboratory members have characterized phenotypes related with the
virulence of C. jejuni (i.e. bile salt resistance, serum resistance, survival in macrophages,
etc) for the cj!428::CAT, c jl430::CAT and KpsM mutants. However, due to variability
observed in the data, particularly for the macrophage assays, these phenotypes were
repeated for all our mutants. In addition, with the construction of a new cj!427:\C A T
mutant, characterization of each phenotype must also be investigated to gain a complete
understanding o f the role o f modified heptoses on the virulence of C. jejuni.

26

CHAPTER 2 - MATERIALS AND METHODS
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2.1

Bacterial strains and culture conditions
C. jejuni ATCC 700819 (NCTC 11168) as well as E. coli DH5a were routinely

cultured from -80°C freezer stocks using conditions suitable for each bacterium. C. jejuni
was grown overnight on Trypticase Soy Agar (TSA; BD, Canada) supplemented with 10
pg/mL vancomycin (Biobasic, Markham, Canada), 5 pg/mL trimethoprim (SigmaAldrich,

Canada), and 5% sheep

blood (Cedarlane, Burlington, Canada). For

transformation purposes, C. jejuni was grown on either TSA plates supplemented with
sheep blood as above or on Mueller Hinton Agar (BD, Canada) plates, containing 10
pg/mL vancomycin, 5 pg/mL trimethoprim, 0.05% pyruvate (Alfa Aesar, USA), and 5%
horse serum (Invitrogen, Canada). Routinely, C. jejuni was grown for up to 48 hours in a
microaerophilic incubator (Nuaire) at 37°C in 5% oxygen, 10% carbon dioxide, 85%
nitrogen, and 90% humidity.

For experiments, wild type and mutant strains (plates

supplemented with appropriate antibiotic(s)) were grown from freezer stocks overnight
and then transferred to TSA plates and incubated for a further 20-24 hours (unless
otherwise stated) before being used. This ensured that C. jejuni was actively growing.
Additional antibiotic(s) were added where appropriate at the following concentrations:
kanamycin (Biobasic, Markham, Canada) 90pg/mL, chloramphenicol (Fisher Scientific,
Canada) 15 pg/mL.
E. coli was routinely grown on lysogeny broth (LB) Agar (Bioshop, Canada) in a
37°C incubator. Alternatively, E. coli was grown in LB broth (Bioshop, Canada) in a
shaking incubator (200 rpm) at 37°C. Antibiotics were supplemented where appropriate
at the following concentrations: 100 pg/mL ampicillin (Biobasic, Markham, Canada), 30
pg/mL kanamycin, and 34 pg/mL chloramphenicol. Where indicated, 5-bromo-4-chloro-
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3-indolyl-P-D-galactopyranoside (X-gal; Biobasic, Markham, Canada) was used at 4
pg/mL.

2.2

Preparation of calcium chloride competent E. coli DH5a
A 3 mL overnight culture of E. coli DH5a grown in LB broth was used to

inoculate 100 mL LB. The bacteria were incubated for 1-2 hours until an ODôooof 0.6
was reached. The bacteria were pelleted at 5000 x g (Eppendorf 5415D, Eppendorf) for
10 minutes at 4°C, re-suspended in 20 mL of cold 50 mM calcium chloride solution and
incubated on ice for 30 minutes. Following this, the bacteria were pelleted as described
above and re-suspended in 5 mL of 50 mM calcium chloride solution and incubated on
ice for 5 hours. After this final incubation period, 5 mL of 50% cold glycerol was added,
and cells aliquoted before storing at -80°C.

2.3

PCR to verify the inactivation of cjl427c in C. jejuni ATCC 700819
For the generation of the cj1427c mutant, a chloramphenicol resistance gene was

inserted into the cjl427c gene. This construct was previously constructed in our
laboratory (100) and used in this thesis. The construct was amplified in E. coli DFI5a and
was verified using cj!427 P2 and P3 primers (see appendix for full list of primers). The
PCR program used was as follows: Initial dénaturation at 94°C for 5 minutes, 25 cycles
of: Dénaturation at 94°C for 45 seconds, Annealing at 49°C for 45 seconds, Elongation at
68°C for 2 minutes, and Final elongation at 68°C for 7 minutes. DNA was amplified
using Expand Long Template (Roche) and was used as per manufacturer’s instruction in
a total reaction volume of 12.5 pL. Once the construct was verified, it was transformed
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into C. jejuni (see below for procedure). The inactivation of the cjl427c gene was
verified using the cj!427 P2 and P3 primers and the same PCR program as above.

2.4

Creation of C. jejuni complementation mutants

The method o f Karlyshev et al was adapted for the creation of the complementation
mutants (87). The 16S -

23S rRNA region was chosen for insertion of the

complementation constructs as three copies of these genes exist within the C. jejuni
genome, and complementation into one of these regions via homologous recombination
will not affect the viability of the bacteria. First, the 16S - 23S rRNA region of C. jejuni
was amplified from wild type genomic DNA using primers 16S rRNA Top - Kpnl and
23S rRNA Bottom - Not I, respectively. The 16S - 23S rRNA fragment (2024 Kb) was
then inserted into the Kpnl/Notl sites of the pBluescript KS (+) cloning vector. This
vector contains an ampicillin resistance gene, as well as a lacZ gene for blue and white
screening. Positive transformants grew as white colonies on LB agar supplemented with
X-gal (4 pg/mL) and ampicillin (100 pg/ mL), indicating that the DNA fragment had
been inserted into the vector. The insertion of the fragment was confirmed by PCR using
fragment specific primers and DNA sequencing (Robarts Sequencing Facility, University
o f Western Ontario, London, Ontario).
The complementation constructs were generated using the primer overlap
extension method, also known as gene SOE-ing (63). In this method, primers used in
PCR contain overlapping sequences of the adjacent DNA fragment to be joined at their 5’
end. Overlapping regions were designed to be at least 21 bases in length. Each DNA
fragment was first amplified individually using Expand Long Template DNA polymerase
(Roche, Canada) and the following PCR program: Initial denaturation at 95°C for 5
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minutes, followed by 30 cycles of denaturation at 95°C for 45 seconds, annealing of the
primers at the appropriate temperature for 45 seconds, elongation at 68°C for the
appropriate duration (1.5 Kb/minute), and a final elongation at 68°C for 7 minutes. The
porA promoter was amplified using primers ompE For - Xbal combined with ompE Rev
1427, ompE Rev 1428, or ompE Rev 1430. The genes to be complemented were
amplified using primers 1427 For ompE, 1428 For ompE, or 1430 For ompE, and their
corresponding reverse primers 1427 Rev Kan, 1428 Rev Kan, or 1430 Rev Kan. The
kanamycin resistance gene was amplified using Kan For 1427, Kan For 1428, or Kan For
1430, combined with the reverse primer AphP3, which contains an Xbal restriction
enzyme site. For the second and third PCR reactions, 9.6 pL (approximately 200 ng) of
each of the fragments to be joined were added to 2.5 pL dNTP (2.5mM), 2.5 pL 10X
Expand Buffer 3, 0.5 pL of forward and reverse primers (20 pmol/pL each) and 0.25 pL
Expand Long Template DNA polymerase. Between each PCR reaction, the products
were run on an agarose gel, and the fragments that corresponded to the correct size were
purified using a gel purification kit (Biobasic, Markham, Canada), according to the
manufacturer’s instructions.
The complementation constructs were then inserted into the multiple cloning site
within the pBluescript vector containing the 16S- 23 S rRNA fragment to generate the
final constructs. Specifically, the restriction endonuclease Xbal was used to cut within the
inserted 16S - 23S rRNA and also to create sticky ends on the complementation
constructs. The vector and the insert was then ligated together using T4 DNA ligase
(New

England

Biolabs).

These

ligated

complementation constructs

were then

transformed into E. coll DH5a and selected on LB agar supplemented with 100 pg/mL
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ampicillin and 30 pg/mL kanamycin. These above steps were done by another student in
our laboratory, Xuan Than Bui. Positive transformants were confirmed via PCR using
OmpE For - Xba\ and AphP3. The correct order of DNA fragments was confirmed by
PCR using primers internal to the constructs. Sequencing of the constructs was performed
at the Robarts Sequencing Facility, University of Western Ontario, London, Ontario.
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Figure 2. Schematic of the complementation constructs used in this study.
The schematic depicts the complementation constructs that were created for the
cjl427::CAT, cjl428::CAT and cjJ420::CAT mutants. The 16S rRNA and 23S rRNA
areas are present to facilitate homologous recombination o f the complementation
construct into the C. jejuni genome. An outer membrane protein promoter, porA, drives
the overall expression of the complementation construct. Due to prior nomenclature,
primers for the porA region have OmpE within their name. Following the promoter is the
gene of interest to be complemented. A kanamycin resistance cassette allows for the
selection of potential complemented clones. The sizes of each fragment are indicated
under their respective regions. Total sizes o f the complementation constructs are
indicated on the right hand side of the figure.
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546 bp
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2.5

Selective methylation of plasmid DNA before transformation of C. jejuni
The method outlined by Donahue et al was adapted for transforming C. jejuni

(36). This method protects foreign DNA from restriction modification enzymes by in
vitro

site-specific

and

strain-specific

methylation.

To have enough DNA

for

transformation, E. coli harbouring the vector of interest was grown and the plasmid
harvested using either a DNA Mini Kit (Qiagen) or an Illustra DNA Midi Kit (GE
Healthcare), depending on whether the vector was a high copy or a low copy plasmid,
respectively. For each kit, the protocol as recommended by the manufacturer was
followed. At least 10 pg of plasmid DNA was treated with a cell-free extract of C. jejuni
(containing 300-400 pg of protein) in the presence of a methyl donor (200 nM Sadenosyl methionine; Sigma Aldrich) before transformation. Methylation was carried out
at 37°C for 1 hour in methylation buffer (20 mM Tris-acetate (pH 7.9), 50 mM potassium
acetate, 5 mM NaiEDTA, 1 mM dithiothreitol (DTT)) in a total volume of 200 pL. To
obtain a cell-free extract, wild type C. jejuni was harvested from five TSA plates and
resuspended in 4 mL of extraction buffer (20 mM Tris-acetate (pH 7.9), 50 mM
potassium acetate, 5 mM Na 2 EDTA, 1 mM DTT, protease inhibitor cocktail (Roche,
following manufacturer’s instructions)). This was passed through a French pressure cell
press (Thermo Scientific) at least five times, until the lysate was visibly clearer. The
amount o f protein in the cell-free extract was quantitated using a Bradford Assay (21)
following

instructions

from the

manufacturer (Biorad).

Following methylation,

phenol:chloroform:isoamyl alcohol (in a 25:24:1 ratio) was used to purify the DNA.
Briefly, one volume of phenol:chloroform:isoamyl alcohol was added to the sample and
agitated to ensure that the aqueous and organic phases mixed. This was then centrifuged
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at maximum speed (16110 x g, Eppendorf 5415D, Eppendorf) for one minute to separate
the layers. The aqueous phase (top phase) was collected, and the organic phase discarded.
An equal volume of phenol:chloroform:isoamyl alcohol was added to the aqueous layer
and the above steps repeated until no visible protein layer was observed between the
aqueous/organic phase interface. The aqueous phase was collected, and to this, an equal
volume of chloroform was added and mixed. This was centrifuged at maximum speed for
1 minute, and the aqueous phase collected. Plasmid DNA was recovered using a sodium
acetate/ethanol precipitation method (see below).

2.6

Sodium acetate/ethanol precipitation of DNA
To recover DNA, a sodium acetate/ethanol precipitation method was used. Briefly,

1/10 volume of 3 M sodium acetate (pH 7.0) was added to the DNA sample. To this, 2.5
volumes o f ice cold 100% absolute ethanol was added. The sample was spun at
maximum speed (16110 x g, Eppendorf 5415D, Eppendorf) for 30 seconds to collect all
the liquid at the bottom of the tube before being placed into the -20°C freezer for a
minimum of 2 hours. The sample was then spun at maximum speed for 30 minutes at 4°C
to pellet the DNA. This was followed by a 750 pL 70% ice cold ethanol wash to remove
excess salts from the DNA pellet. The sample was spun again at 4°C at maximum speed
for 15 minutes. The ethanol was removed, and the DNA pellet allowed to air dry before
being resuspended in 50 pT sterile water. Plasmid DNA purified in this manner was
stored at -20°C until required.
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2.7

Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments. For most DNA

fragments, a 0.7% agarose gel was prepared in TAE buffer (40 mM Tris-acetate pH 8.0, 1
mM EDTA), and ethidium bromide was added to a final concentration of 0.01%. For
smaller fragments (~200 bp), a 1.4% agarose gel was prepared in a similar manner as
above. Samples were mixed with DNA loading buffer (4x TAE buffer, 50% glycerol,
0.01% bromophenol blue) before loading and sizes were compared to a 1 kilobase pair
(Kb) DNA ladder standard (Invitrogen, Frogga). Electrophoresis was carried out at 80
volts until proper separation was achieved. DNA bands were visualized using UV light.

2.8

Preparation of C. jejuni and electroporation procedure
C. jejuni was grown on TSA supplemented with 5% sheep blood for 24 hours in

microaerophilic conditions. On the day o f transformation, 4-5 plates of the bacteria were
suspended in 1 mL of 15% glycerol/272 mM sucrose and spun down for 2 minutes at
3300 x g. The cells were washed three times with 1 mL of cold 15% glycerol/272 mM
sucrose before being resuspended in 150 pL ice cold 15% glycerol/272 mM sucrose. The
OD 600 was taken and samples diluted or concentrated to obtain approximately 109
cells/mL. An OD6ooof 1.0 corresponds to approximately 109 cells/mL, as determined by a
standard curve of colony forming units (CFU) versus OD60o- Transformation was done
with 70 pL of cells and 2 pg of plasmid DNA in a total volume of 80 pL. A negative
transformation control consisted of 70 pL of cells and 10 pL of water. Prior to
electroporation, cells were plated on TSA plates to ensure their viability. Cells were then
transferred to an ice cold 0.2 cm electroporation cuvette (Gene Pulser) and electroporated
at 2.5 kvolts, 600 D, 25 pF. Cells were placed back on ice, and 300 pL of Mueller Hinton
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(MH) or TSA broth added to the cells. Four spots of 75 pL each were placed onto MH
plates or TSA plates supplemented with 5% sheep blood and cells allowed to recover for
a minimum o f 5 hours under microaerophilic conditions at 37°C. Alternative recovery
times of 8 hours and 10 hours were also attempted. After each recovery time period, spots
were resuspended in 300 pL of MH broth or TSA broth and 75 pL plated onto MH or
TSA agar plates containing selective antibiotics, respectively, using glass beads. Plating
onto MH or TSA plates, to ensure viability after electroporation, was also done in parallel.
These plates were grown for 2-3 days under microaerophilic conditions at 37°C until
colonies were observed.

2.9

Preparation of C. jejuni and natural transformation procedure
C. jejuni was grown on TSA supplemented with 5% sheep blood for 24 hours in

microaerophilic conditions. On the day of transformation, 2 plates of the bacteria were
suspended in 1 mL o f TSA broth. The ODeoo was taken and samples diluted or
concentrated to obtain approximately 109 cells/mL. Transformation was done with 70 pL
o f cells and 2 pg of plasmid DNA in a total volume of 80 pL. A negative transformation
control consisted of 70 pL of cells and 10 pL of water. The plasmid was mixed with the
bacteria, and to this, 300 pL o f TSA broth was added to the cells. Four spots o f 75 pL
each were placed onto TSA plates supplemented with 5% sheep blood and cells allowed
to recover for a minimum of 5 hours under microaerophilic conditions at 37°C.
Alternative recovery times of 8 hours and 10 hours were also attempted. After each
recovery time period, spots were resuspended in 300 pL o f TSA broth and 75 pL plated
onto TSA agar plates containing selective antibiotics using glass beads. Plating onto TSA
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plates, with no antibiotics, to ensure viability after transformation, was also done in
parallel. These plates were grown for 2-3 days under microaerophilic conditions at 37°C
until colonies were observed.

2.10

Colony PCR
Colony PCR was used to verify potential transformants. Colonies were picked

from an agar plate and resuspended in 15 pL of water. 5 pL was added to a PCR reaction
with 12.5 pL as the final volume. The PCR reaction mix contained IX Expand PCR
Buffer 2, 0.25 mM dNTP, 20 pmol of each primer, and 1U Expand Long Template. The
PCR conditions used for the reaction were as follows: 94°C (initial denaturation) for 10
min, 94°C (denaturation) for 45 seconds, annealing temperature at the appropriate
temperature for 45 seconds, 68°C (elongation) for X min, where X is the appropriate
duration dependent on the length o f the fragment to be amplified) cycled 25 times,
followed by 68°C (final elongation) for 7 min.

Products were run on a 0.7% DNA

agarose gel as described above.

2.11

Preparation of genomic DNA from bacterial pellets
C. jejuni was grown on 1 TSA agar plate for 24 hours under microaerophilic

conditions at 37°C and then resuspended in 1 mL of TSA broth. Samples were
centrifuged for 5 minutes at 16100 x g (Eppendorf 5415D, Eppendorf). The supernatant
was removed, and 1 mL of DNAZol (Invitrogen) reagent was added and the sample
mixed well. The samples were incubated at room temperature for 60 minutes to allow the
cells to lyse. After incubation, samples were spun for 10 minutes at 9300 x g to remove
any debris. The supernatant was collected to a new 1.5 mL centrifuge tube. Five hundred
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fj.L of ice cold 100% ethanol was added and the tube inverted 5-10 times. Samples were
then placed at -20°C for 45 minutes to allow the DNA to precipitate. Following this, the
DNA was pelleted via centrifugation for 10 minutes at 16100 x g and the DNAzol
supernatant removed. Pellets were washed twice with 500 pL 95% ethanol, and spun at
16100 x g for two minutes. Following the last wash, the ethanol was removed, and the
pellets air dried at room temperature for 30 minutes. The DNA was dissolved in 30-50
pL o f water, and left overnight at 4°C. The following day, samples were placed at 37°C
for 30 minutes to allow DNA to dissolve further. DNA prepared in this manner was
stored at 4°C until further required.

2.12

Preparation of C. jejuni RNA and cDNA
C. jejuni was grown for 20-24 hours under microaerophilic conditions at 37°C on

one TSA plate. For RNA isolation, no more than 5.0 x 109 cells were resuspended in 200
pL TE buffer, as recommended by the manufacturer, prior to lysis. RNA was isolated
using the RNA midi spin kit (GE Health Sciences) as per the manufacturer’s instructions.
The final elution step was done in 500 pL of RNAse free water, following the
manufacturer’s instructions. In addition to the on column DNAse I treatment as suggested
by the manufacturer, the samples were treated using 60 units o f DNAse I (Roche,
Canada) for 40 minutes at 37°C. Following the reaction, the DNAse was inactivated via
the addition of 8.4 pL 100 mM ethylenediaminetetraacetic acid (EDTA) and heating at
70°C for 10 minutes. The remaining EDTA was titrated via the addition of excess M gC f
in diethylpyrocarbonate (DEPC)-treated water to a final concentration of 11 mM. The
amount of RNA was quantified using a ND-1000 Nanodrop spectrophotometer
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(Nanodrop, USA). RNA samples were diluted in DEPC-treated water to a final
concentration of 10.5 ng/pL. cDNA was generated using ¿Script reverse transcriptase
(BioRad, Canada). Each reaction contained 30 pL of DNAse-treated RNA, 8 pL 5x
iScript reaction mix, and 2 pL of iScript reverse transcriptase. Negative control samples
contained 10 pL of the iScript reaction mix and 30 pL of RNA. The reverse transcription
reaction was carried out using a BioRad thermocycler (BioRad, Canada) and the program
used was as follows: 5 minutes at 25°C for annealing of the random primers, 30 minutes
at 42°C for extension, 5 minutes at 85°C for inactivation of reverse transcriptase, and a
final 4°C hold. Following the generation of cDNA, the samples were stored at -20°C until
use.

2.13

Real-time PCR analysis

Real-time PCR analysis was carried out using the Rotor-Gene 6000 (Corbett
Life Science, Canada) to measure the transcription levels of the cj1425c, cj1426c,
cjl427c, cjl428c, cj!429c, cjl430c, cjl444c, cjl445c, cjl447c and kpsM genes in the
wild type and mutant strains. The gene cj1537c encoding an acetyl CoA synthetase (a
housekeeping gene) was used as a reference for normalization within each strain
(intrastrain).

C. jejuni chromosomal DNA was used as a positive control for the

amplification of each fragment. When determining the expression level of each gene of
interest, samples were set up in triplicate. For determination of gene expression, 3.75 pL
o f cDNA were added to 1.34 pL o f the appropriate primer mix (0.67 pL of each primer,
at 7 pmol/pL (see Appendix for primer sequences)), 7.5 pL SYBR green mix, containing
all necessary components for RT-PCR, (BioRad, Canada), and 2.4 pL of water. Negative
controls for the RT-PCR contained cDNA but did not contain the SYBR Green mix. An
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additional negative control consisted of the SYBR Green mix and RNA which did not
undergo reverse transcription. This control was used to ensure there was no chromosomal
DNA contamination.
Reactions were carried out as follows: 95°C (initial dénaturation) for 5 minutes,
95°C (dénaturation) for 45 seconds, 59.5°C (annealing) for 30 seconds, and 72°C
(elongation) for 20 seconds. Steps 2-4 were repeated for 40 cycles.
For each primer pair, efficiencies were determined using the dynamic range of
chromosomal DNA and amplifying the desired fragments. Following amplification, the
data were plotted and a standard curve was generated based on the CT (the cycle number
at which enough amplified product accumulates to yield a detectable fluorescence signal
above a set threshold) values for the amplification from the different chromosomal DNA
concentrations covering the dynamic range. The primer amplification efficiency was
determined from the slope of the standard curve by performing the following calculation:
E (efficiency) =

|Q-i/siope^

was converted into a percentage using the

following: %Efficiency = (E -l) x 100.
The dynamic range o f cDNA for downstream real-time PCR analysis was
determined using varying concentrations of cDNA. For this, DNA fragments were
amplified from serial dilutions of cDNA. The Ct value for each reaction was determined
and a standard curve was generated by plotting CT against the cDNA concentration. The
cDNA concentrations yielding the best standard curve (i.e. the C j values were evenly
spaced and a linear standard curve results in a slope indicative of the maximum
amplification efficiency (i.e. a doubling o f DNA per cycle)) were used in each
experiment to determine gene expression.
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Two methods o f comparison were used to determine differences in gene
expression: intrastrain and interstrain comparisons. In intrastrain comparisons, the fold
difference of expression of each gene was normalized to an internal housekeeping gene,
cj1537c (a gene which encodes acetyl CoA synthetase). For interstrain comparisons, the
fold expression of each gene was first normalized to the housekeeping gene in each strain
as above, and then taken as ratio over the respective genes in the wild type. This was
calculated using the Pfaffl equation, which is as follows: Ratio = (£'target)ACTtar8et(cal'brator"
test)/ ( £ 'ref)ACTref(callbrator' ,est)

(135). The target gene refers to the gene being studied, the

reference is cj1537c, the calibrator refers to the wild type strain, while the test refers to
the knockout mutant of interest. Note that for intrastrain comparisons, a modified Pfaffl
equation can thus be used, whereby the equation is simplified to the following: Ratio =
(Z?

2.14

, y-CTtargetcalibrator) j

y-CTrefcalibrator)

Growth curves of ATCC 700819 wild type and mutant strains
C. jejuni was grown as described above and re-suspended in MH broth to an

OD 600 of 1.0. A sidearm flask containing 20 mL MH broth and background antibiotics
was first saturated with nitrogen by allowing the gas to bubble into the media for
approximately 5 minutes through a sterile Pasteur pipette which was inserted into the
flask, and partially sealed with a rubber stopper. The MH broth was then inoculated with
1.5 mL of the bacterial suspension to achieve a starting O D 6oo of 0.075. Nitrogen gas was
bubbled into the sidearm flask for a further 10 minutes, to allow gas to fill the remaining
volume of the flask, creating a microaerophilic environment. The flasks were then sealed
and incubated under agitation (120 rpm) at 37°C for up to 24 hours. Growth was
monitored using a Klett colony meter (600 nm filter) over 24 hours.
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2.15

Motility assay
C. jejuni cells were harvested in MH broth and adjusted to an OD 600 of 1.0.

Motility plates (0.3 % Bacto agar (Difco) in MH broth supplemented with 5% horse
serum) were inoculated (via stabbing from equal volumes) in multiple replicates with
wild type or mutant strains and incubated for 48 hours under microaerophilic conditions
at 37°C. The diameter o f the motility halo was measured after 48 hours.

2.16

SDS-polyacrylamide gel electrophoresis
SDS-PAGE was performed using either polyacrylamide gels consisting of a 10%

separating gel and a 4.8% acrylamide stacking gel or tricine gradient gels (10-20%,
Biorad, Canada). For the polyacrylamide gels, the separating and stacking gels were
made using 0.8% bis-acrylamide. Gels were run in Tris-glycine running buffer (25 mM
Tris pH 8.3, 192 mM glycine, 1% w/v sodium dodecyl sulfate (SDS)) at 12 mA through
the stacking gel and at 15 mA through the separating gel. Tricine gradient gels were run
in cathode buffer (0.1 M Tris (the pH is not adjusted, but should be approximately 8.25),
0.1 M tricine, and 0.1% SDS) and anode buffer (0.2 M Tris, pH 8.9) at 12 mA through
the stacking gel and at 15 mA through the separating gel.

2.17

Western blotting
Crude CPS and LOS samples were prepared by SDS-solubilization as previously

described by Hitchcock and Brown (68). Briefly, C. jejuni from one TSA plate was
resuspended into 1 mL of PBS and pelleted at 16100 x g (Eppendorf 5415D, Eppendorf).
The resuspended bacteria were diluted to an OD 600 of 0.375 and 1 mL aliquoted. This
aliquot was respun at 16100 x g to pellet the bacteria. The bacterial pellet was
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resuspended in 200 pL of SDS solubilization buffer (2% SDS, 4% 2-mercaptoethanol,
10% glycerol, 1 M Tris pH 6.8, bromophenol blue) and boiled for 10 minutes. To each
sample, 5 pL of 20 mg/mL Proteinase K was added and incubated for one hour at 60 °C.
Samples were run on a SDS-PAGE gel as described above.
After SDS-PAGE separation, the gel was placed into a BioRad transfer apparatus
and transfer occurred for one hour at 180 mA. A PVDF membrane (Biorad) pre-wetted in
methanol was used for transfer. Transfer buffer consisted of 192 mM glycine, 25 mM
Tris, 20% methanol, and 0.01% SDS. Membranes were blocked overnight with 2.5%
skim milk at 4°C. Membranes were incubated with the primary antibody (IgG antiCampylobacter, Santa Cruz, California) (1:100 and 1:200 in TBS; 1:1000 anti-lipid A
antibody - kindly provided by Dr. J. S. Lam, University of Guelph) for one hour at room
temperature. Membranes were then washed two times for 10 minutes in Tris buffered
saline (TBS) plus 0.05% (v/v) Tween 20 and 0.2% (v/v) Triton X-100 and then once in
TBS for 10 minutes. The secondary antibody for the anti-Campylobacter antibody and
for the anti-lipid A antibody was the goat anti-mouse 800 nm (full) antibody (Licor). The
membranes were incubated for 30 minutes with the secondary antibody (1:2500 in TBS),
followed by three washes with TBS plus 0.05% (v/v) Tween 20 and 0.2% (v/v) Triton X100. Carbohydrates were visualized using the Licor scanning system.

2.18

Silver staining
The silver staining protocol o f Fomsgaard et al was followed (42). Briefly,

carbohydrates were first separated on a 10% SDS-PAGE and then oxidized in a solution
of 0.7% periodic acid, 40% ethanol and 5% acetic acid in reverse osmosis water with
shaking for 20 minutes. The oxidation was followed by five washes over 15 minutes in
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reverse osmosis water. The gel was then stained with silver nitrate in a staining solution
with the following final concentrations: 0.19% (v/v) 10 N NaOH, 1.3% (v/v) ammonium
hydroxide, 0.7% (w/v) silver nitrate. Gels were stained for 10 minutes, followed by five
washes over 15 minutes in reverse osmosis water. Following the washes, the gels were
developed using 0.005% (w/v) citric acid and 0.05% (v/v) formaldehyde (37%) in reverse
osmosis water until bands became visible. The gels were then washed several times with
reverse osmosis water and scanned.

2.19

Purification of C. jejuni CPS
For the purification of CPS from C. jejuni ATCC 700819 wild type and

cjl427::CAT, cj1428v.C A T, cj!430::CAT, KpsM and cj!427::CATA mutants, strains
were grown on TSA plates as aforementioned for 24 hours and harvested in saline. To
obtain sufficient capsular material for downstream processing, approximately 100 TSA
plates were first grown, and then inoculated into 10 L of Brucella broth (BBL Sciences,
Canada), containing 7.5% horse serum and 25 mM sodium pyruvate to an OD 600 of
approximately 0.05. After 24 hours o f growth (O D 6oo approximately 0.3), the bacteria
were spun down at 4200 x g (Avanti J-25I, Beckman-Coulter) for 30 minutes. The pellets
from 10 L o f growth were combined, and then lyophilized to obtain a dry sample.
Purification of CPS was performed using the hot water/phenol extraction method (171).
Briefly, a dry cell pellet of approximately two grams was re-suspended in 20 mL of
MilliQ water pre-heated to 68°C. An equal amount of liquified phenol (Fisher) preheated
to 68°C was added to the pellet and sealed in a 50 mL Falcon tube. The samples were
incubated in a 68°C water bath for 10 minutes with rapid stirring.

The sample was

allowed to cool to 10°C on ice and centrifuged for 30 minutes at 6300 x g (Eppendorf
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581 OR, Eppendorf), and 10°C.

The aqueous (top) phase was collected, and an equal

amount o f water was added to the remaining organic phase. The procedure was repeated
a total of three times and the aqueous phases were pooled. The aqueous phases were
dialyzed (molecular weight cut off 12-14000 Da, Spectra/Por, Spectrum Labs) against
running water for 2-3 days until no phenol remained. The sample was lyophilized and re
suspended in double distilled water. Ultracentrifugation of the sample for 30 hours at
4°C and 110000 x g (Optima Max-XP Ultracentrifuge, Beckman-Coulter) pelleted most
of the LOS, while CPS remained in the supernatant. The sample was lyophilized and re
suspended in 500 pL double distilled water. Treatment with 200 mg of Proteinase K
(Biobasic, Markham, Canada) was carried out for two hours at 60°C to degrade any
remaining proteins that may not have been removed during the hot water/phenol
procedure. CPS samples were stored at -20°C until further required.

2.19.1

Via size exclusion chromatography
Size exclusion chromatography was used in an attempt to separate the smaller

LOS molecules away from larger CPS molecules. Hot water/phenol purified samples
were run with water as the eluent through a size exclusion column measuring 87.2 cm by
1.6 cm (length x diameter) containing Bio-Gel P6 resin (BioRad - 1000 - 6000 Da
fractionation range).

Other resins used included the G25 (Sigma Aldrich - 5500 Da

exclusion) and the G50 (Sigma Aldrich - 10000 Da exclusion) matrices. Dextran Blue
was run to determine the void volume. Fractions were collected for one full column
volume, in 1 mL increments. Silver staining was used to verify the presence or absence
of LOS in the samples.
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2.19.2

Via acetic acid treatment
The method used by Aspinall et al (10) was used in an attempt to partially

hydrolyze the linkage between Kdo and the lipid A core. Briefly, to a sample of CPS,
acetic acid was added to a final concentration o f 1% and heated at 100°C for one hour.
Any remaining acid was neutralized with 2 M ammonium bicarbonate. Ammonium
bicarbonate was added until the solution reached a neutral pH of 7.0. Precipitated lipid A
was removed via centrifugation at 5000 x g for 5 minutes (Eppendorf 5415D, Eppendorf)
and the supernatant lyophilized and resuspended into 500 pL double distilled water.
Samples were stored at -20°C until further required.

2.19.3

Via ammonium acetate treatment
Similar to the method used by Aspinall et al (10), ammonium acetate is a method

that will partially hydrolyze the linkage between Kdo and the lipid A core. However, this
method is less harsh than acetic acid, and is less likely to degrade CPS. CPS was treated
with 50 mM ammonium acetate at pH 4.5 for 90 minutes at 100°C. Samples were then
neutralized with 2 M ammonium bicarbonate. Ammonium bicarbonate was added until
the solution reached a neutral pH of 7.0. Precipitated lipid A was removed via
centrifugation at 5000 x g for 5 minutes (Eppendorf 5415D, Eppendorf) and the
supernatant lyophilized and resuspended into 500 pL double distilled water. Samples
were stored at -20°C until further required.

2.19.4

Via sodium deoxycholate
The method outlined by Gu and Tsai (1990) was adapted to attempt to purify EOS

away from CPS (53). Briefly, raw CPS was processed as above, and the ultracentrifuged
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pure samples were resuspended into 500 pL of water. To this, sodium EDTA was added
to a concentration of 2 mM, and the pH adjusted to 8.5 with 1 M NaOH. Sodium
deoxycholate was added to the mixture to a final concentration of 2% (w/v) and
incubated at 37°C for 10 minutes. This was then run on a column containing Sephadex
G50 beads using 20 mM Tris, 2 mM EDTA, and 1% sodium deoxycholate (w/v), pH 8.5
as the eluent.

2.20

Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance was conducted as previously mentioned (69, 94).

2.21

Assessing the susceptibility of C. jejuni wild type and mutants to various
compounds

2.21.1

Bile salts
C. jejuni cells were washed once in saline and re-suspended to an OD 600 o f 0.1.

Bile salts (50%/50% w/v cholate and deoxycholate - Sigma-Aldrich) were diluted to the
appropriate concentrations (0, 0.25, 0.5, 0.75. 1.0, and 2.0 g/L) and 90 pL aliquoted into
the wells of a 96 well plate. 10 pL of bacteria was added to each well and incubated in
microaerophilic conditions at 37°C for 15 minutes. Samples were washed once in TSB
media and serially diluted for colony forming unit (CFU) counts. For this, 10 pL of each
dilution, over a range o f dilutions was taken and spotted onto a square culture plate
containing TSA and background antibiotics. Each spot was done in duplicate. The plates
were incubated in microaerophilic conditions at 37°C for 36 hours and the CFU counts
enumerated. Experimental results were normalized to the CFU counts of bacterial
samples that did not receive any bile salt treatment.
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2.21.2

SDS
Different concentrations (0.002%, 0.003%, 0.004%, 0.005%, 0.0075%, 0.01%,

0.015%, 0.02% and 0.03%) of SDS were prepared in TSB (+ vancomycin and
trimethoprim), using 1% (w/v) SDS as a stock solution. 170 pL of each concentration of
SDS was added to an appropriate number o f wells o f a 96 well plate. C. jejuni wild type
and mutants were grown as previously described and re-suspended in TSB to an OD 600
1.0. To each well, 30 pL of bacterial suspension was added, and controls wells were set
up which contained 200 pL TSB. The plates were incubated at 37°C with shaking at 180
rpm in microaerophilic conditions for 15 hours, at which point the O D 6oo was read.
Experimental results were normalized to bacteria which did not receive any SDS
treatment.

2.21.3

Serum
Fresh rabbit blood (from two rabbits; 6 mL each) was obtained the morning of the

experiment from Animal Care and Veterinary Services at the University of Western
Ontario. The blood was incubated at room temperature for 1-2 hours, until the blood had
visibly clotted. The serum was separated from the clot and centrifuged for 15 minutes at
9300 x g at 4°C (Eppendorf 5870R, Eppendorf) to remove remaining blood cells. Half of
the serum was inactivated by incubation at 60°C for one hour. Bacteria grown for 24
hours on TSA were washed in saline and re-suspended to an OD6oo of 0.1. Serum
(inactivated or not) was diluted in saline to the appropriate concentrations (0% - 100%)
and 90 pL was aliquoted into the wells of a 96 well plate. To the wells, 10 pL of bacteria
was added. The plates were then incubated with agitation (100 rpm) for 1.5 hours in
microaerophilic conditions at 37°C. Following incubation, 100 pT TSB was added to the
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wells and samples were serially diluted and plated for CFU counts. Enumeration of the
CFU was done after incubation for 36 hours in microaerophilic conditions.
For time course experiments, bacterial samples were tested at 20% pooled rabbit
serum for 1.5 hours.

2.22

Assessing the adhesion and invasion of C. jejuni in Caco-2 cells
Caco-2 colorectal epithelial cells (kindly given by D. McKay, University of

Calgary) were routinely grown on 75 cm2 tissue culture flasks in DMEM medium
containing high glucose (25 mM) and supplemented with 10% fetal bovine serum (FBS,
Gibco), 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium
pyruvate, 100 U/mL penicillin, and 100 pg/mL streptomycin. Caco-2 cells were grown
in a CO 2 incubator containing 5% CO 2 and 37°C until confluent, and passaged every 4-5
days. Passage of Caco-2 cells was carried out by releasing the cells from the flask surface
via the addition of 0.25% Trypsin/EDTA (Gibco), followed by incubation in the CO 2
incubator at 37°C for 2-3 minutes. Once released, the trypsin/EDTA was neutralized via
the addition of fresh DMEM. Cells were then centrifuged at 200 x g (Eppendorf 5702,
Eppendorf) for 5 minutes to remove any excess trypsin.
Caco-2 cells were grown for three days until they formed a confluent monolayer
(approximately 6.5 x 103 cells per well in 24-well plates). The cells were infected for 5
hours with wild type or mutant C. jejuni. Approximately 6.5 x 10 CFU of C. jejuni were
added, resulting in a multiplicity of infection o f 100. The plates were spun briefly (300 x
g (Eppendorf 5870R, Eppendorf) for 5 minutes at room temperature) to maximize contact
between the bacteria and the cell monolayer. To determine total bacterial cell association
(adherent and internalized bacteria), Caco-2 cell monolayers were washed three times,
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lysed with 0.1 % Triton X-100 for 10 minutes and viable bacterial counts were
determined by plating the serial dilutions.
To determine the number of internalized bacteria, the Caco-2 cell monolayers
were treated with 200 pg/mL gentamicin for two hours to kill extracellular bacteria. The
cells were then washed and treated as above to determine bacterial viable counts.

2.23

Assessing the interaction of C. jejuni with RAW 264.7 macrophages
RAW 264.7 macrophages (ATCC) were grown in 75 cm2 tissue culture flasks

(BD Falcon) in DMEM (Invitrogen) containing high glucose (25 mM), 10% FBS, 0.1
mM non-essential amino acids, 100 U/mL penicillin, and 100 pg/mL streptomycin in a
CO 2 incubator containing 5% CO 2 and at 37°C. They were grown from freezer stocks
until 80% confluent and then passaged every 3-4 days to a maximum of 5 passages.
Passaging involved washing the macrophages in lx PBS (Wisent) and detaching them by
the addition o f 5 mL 0.25% Trypsin/EDTA (Gibco) and incubation in a CO 2 incubator
for 2-3 minutes. The cells were detached by allowing 15 mL of fresh DMEM to run over
them. Cells were then centrifuged at 200 x g (Eppendorf 5702, Eppendorf) for 5 minutes
to remove any excess trypsin. To seed new cells, 1 mL of cells was taken and added to 19
mL o f fresh DMEM medium in a 75 cm2 flask and incubated in a CO 2 incubator until
needed.
Freezer stocks of the macrophages were made with 45% cells, 45% FBS and 10%
dimethyl sulfoxide (DMSO, Sigma-Aldrich). Cells were aliquoted into 2 mL cryotubes
and stored at -80°C until required.
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For experiments, cells were first counted using a hemocytometer. For this, 10 pL
o f the cell suspension was loaded onto a hemocytometer and the number o f cells was
counted in five independent squares. The average number of cells was used.
Cells were then seeded at approximately 2.1 x 105 cells per well of a 24 well plate
and incubated overnight in DMEM without antibiotics. C. jejuni wild type or mutants
were added at a multiplicity o f infection (MOI) of 100. The plates were centrifuged for
two minutes at 300 x g (Eppendorf 5870R, Eppendorf) to synchronize bacteriamacrophage interaction.
For adhesion experiments, the plates were incubated with bacteria at 4°C for 30
minutes, washed with cold PBS five times and the cells were lysed in sterile double
distilled water. The bacteria were then serially diluted and plated for CFU counts.
For intracellular survival experiments, cells were seeded as above and infected
with bacteria at an MOI of 100 for two hours in a 5% CO2 incubator. The cells were
washed three times using PBS and incubated with fresh DMEM containing 225pg/mL
gentamicin for one hour to kill extracellular bacteria. Macrophages were then washed
and incubated in fresh DMEM for the times indicated.

At each time point, the

macrophages were washed three times with PBS and lysed using sterile double distilled
water. Samples were serially diluted and plated for CFU counts.
For infection time course experiments, macrophages were seeded as above and
infected with bacteria at an MOI of 100 for the times indicated. The macrophages were
washed three times in PBS and incubated in fresh DMEM containing 225 pg/mL
gentamicin for one hour, followed by lysis as described above and surviving bacteria
were enumerated by CFU counts.
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2.24

Autoagglutination assay
The agglutination assay was performed as previously described (115). Briefly, 2

mL of sterile PBS was inoculated with C. jejuni wild type or mutants at OD ôoo 1.0. At
time points 0 hour, 1 hour, and 2 hours, the top 1 mL from each tube was carefully
removed and the ObLoo was read. The value obtained represents bacteria that have not
agglutinated, as agglutination leads to the settling of bacterial clumps to the bottom of the
tube.

2.25

Statistical analysis
Statistical analysis was carried out using the one-way ANOVA statistical test

followed by a Dunnett’s multiple comparison test. Results were considered significant if
the p value was less than 0.05.
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CHAPTER 3 - RESULTS
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3.1

THE GENERATION AND GENETIC CHARACTERIZATION OF CPS
MUTANTS
At the start of this project, the availability of structural data for C. jejuni capsular

polysaccharide (CPS) was scarce. It was known that some C. jejuni strains possessed
modified heptoses, and that these modified heptoses formed a major structural component
of the CPS (9, 10). Generation of a random C. jejuni ATCC 700819 DNA library and
subsequent sequencing revealed protein encoding genes similar to the CPS biosynthetic
genes of other bacteria (84). These findings were confirmed when the C. jejuni ATCC
700819 complete genome was sequenced, revealing a gene cluster that was similar to the
group II and group III CPS biosynthesis genes found in E. coli. Inactivation of these
genes did not result in the loss of low-molecular weight lipooligosaccharide (LOS)
molecules, but instead, the loss o f a then unknown high-molecular weight species (86).
The combination of these findings led to the realization that these high-molecular weight
molecules were indeed CPS, and not LPS, as was originally thought. However, the exact
genes that were involved in modifying heptoses remain unknown, even to the present.

3.1.1

The principle of C. jejuni mutant generation
Previous work in the Creuzenet laboratory (100) provided C. jejuni mutants

containing disruptions in cjl427c, cj1428c, cjl430c and KpsM. These genes were chosen
to be disrupted as they are hypothesized to be involved with either modified heptose
synthesis {cj1427c, cj 1428c, and cj1430c) or the export of the final capsular
polysaccharide (KpsM). Briefly, these genes were first inserted into a pET23::MTF
vector, while the KpsM gene was inserted into a pBluescript KS (+) vector. Subsequent
inverse PCR using primers that were internal and divergent to the genes of interest
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yielded open pET23::c/1427, pET23::cjl428, pET23::cj1430 and pBhieKSxAi/wM. Into
these, either the C. coli chloramphenicol resistance gene derived from p R Y l l l (177) or
the kanamycin resistance gene aph3 from H. pylori shuttle vector pHel3 (66) was inserted
to generate the disruption construct.

3.1.2

Further analysis of the cjl427::CAT mutant reveals multiple deletions
At the outset o f this project, real-time PCR data suggested that the previously

generated cj!427::CAT (hereafter referred to as cj 1427::CA'YA) mutant possessed
additional gene deletions. It was found that the expression levels of the cjl426c and
cj1425c genes in this mutant were zero, which hinted at their potential deletion. To
investigate this, conventional PCR was done to determine the presence or absence of
genes downstream of the inserted antibiotic resistance cassette. Using primers that
annealed to cj1427c and cj 1418c, a large size discrepancy was observed between the wild
type and the cj!427::CATA mutant, indicating that a deletion was present (Figure 3A).
Following this, primers annealing to cj1426c and cjl425c were used and it was observed
that the cjl427::CATA mutant did not yield a band of the expected size, indicating that
one o f these two genes was deleted (Figure 3B). Further PCR using primers that
annealed to cjl426c and cjl427c as well as cjl427c and cj!425c also failed to generate
bands o f the expected size, confirming that both cjl426c and cjl425c are deleted in the
cjl427::CATA mutant (Figure 3C). A final PCR using primers annealing to cjl421c and
cjl418c also failed to generate a band o f the expected size for the cjl427::CATA mutant,
indicating that the genes from cjl426c to cjl421c are deleted (Figure 3D). In all
reactions, a kpsM gene control was also conducted in parallel to rule out problems with
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the chromosomal DNA preparation (i.e. conditions that may lead to inhibitions in the
PCR reaction).
To determine the precise location of this deletion, and also to map the junction at
which the C. jejuni genome was disrupted, PCR samples of the cjl427\:CATA mutant
were sequenced (Robarts Research Institute, London, Ontario). It was found that the area
between cjl421c and cjl427c was deleted; specifically, the first 998 bp of the cjl421c gene
were deleted, leaving only the last 840 bp. The sequence then proceeds directly into the
cj1427c gene. This deletion of approximately 6.1 Kb agrees with the results of
conventional PCR.
The deletion of these genes will have several profound effects on C. jejuni. Firstly,
cj1426c is a putative methyltransferase involved in the methylation of carbon six on the
heptose; its deletion would result in the lack of this modification. However, more
importantly is the fact that cj1425c - cj1423c are involved in the synthesis of the heptose
precursor (GDP-g/ycero-miwno-heptose). The deletion o f these genes means that the
mutant will lack a heptose of any kind, and thus, the deletion of cj1426c is redundant, as
there is no heptose for the methyltransferase on which to act. Past the genes involved in
the synthesis of the heptose precursor are genes cjl422c and cjl421c. Deletions in these
genes will have additional effects on the capsule. Based on results found by McNally et
al (114), cj1422c and cj 1421c are responsible for transferring the phosphoramidate group
to C-4 of D-g/ycero-a-L-g/wco-heptopyranose and C-3 of the p-D-Gal/Nac residue,
respectively. In C. jejuni strain ATCC 700819, the phosphoramidate group was found
only to be attached to the p-D-Gal/Nac residue and not the heptose. Since the gene
responsible for the transfer of the phosphoramidate moiety is non-functional, not only is
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this mutant heptoseless, but it also lacks the capsular attached phosphoramidate. The
downstream phosphoramidate synthesis genes (cjl415c - cjl4l8c) are not disrupted, and
synthesis of phosphoramidate still occurs. The final result of these deletions is a mutant
with a straight-chain capsule; one that is free of both heptose and phosphoramidate sidebranches. While this mutant was not the one that was initially desired, it is still of use in
our laboratory as it can be used to study if the absence of side-branches in the capsular
structure result in changes in C. jejuni virulence. This mutant was thus assigned the name
cjI427::CATA, with the A to indicate that a large portion o f the genes in the capsular
cluster had been deleted.
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Figure 3. Characterization of the c jl4 2 7 ::C A T A mutant.
In all panels, a schematic shows the region of the C. jejuni genome that was amplified; small
arrows above and below the genome represent the primers that were used. The box within the
cj1427c gene represents the chloramphenicol resistance cassette that was inserted. An inset
table shows the sizes of the expected PCR products for both the wild type and the
cjl427::CATA mutant strain. Samples were loaded in multiple replicates with each
representing a dilution of template DNA used for PCR. The kpsM gene was amplified as a
positive control for the chromosomal DNA preparation. The expected size of this band is 835
bp in both wild type and the cj]427::CATA mutant. A) A deletion is present in the

cj!427::CATA mutant. A significant size difference is observed between the cj1427::CATA
strain and the wild type strain in the capsular cluster of genes between cj1427c and cj 1418c.
Parts of the C. jejuni genome are not shown, and are represented by a double slash (//). B)
One of cjl425c or cjl426c is not present in the cjl427::CAYA mutant. No fragment of the
expected size is observed for the cjl427\:C AT A mutant. However, a fragment of the
expected size is observed in the wild type strain. C) The genes cjl426c and cjl425c are not
present in the cjl427::C AT A mutant. No fragments of the expected sizes are observed in
the cjl427::CATA mutant, while bands of the expected size are observed in the wild type
strain indicating that cjl426c and cjl425c are deleted in the cj!427::CATA mutant. D) The
gene cjl421c is not present in the cjl427::C AT A mutant. A fragment of the expected size
was not observed for the cjl427:\CATA mutant, while the same band was observed in the
wild type strain, indicating that a large fragment of the C. jejuni genome, up to and including
cj 1421c, is not present.
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62

Creation and verification of a new C. je ju n i c jl4 2 7::CAT mutant
To complete our panel o f C. jejuni mutants exclusively deficient in the heptose

modification pathway, a new cjl427::CAT mutant needed to be constructed. The

cjl427::CAT construct was previously made in our laboratory and was already on a pET
plasmid (100). To mobilize this plasmid into wild type C. jejuni, barriers had to be
overcome. Due to the large number o f restriction endonucleases within C. jejuni, it is
often quite difficult to transform foreign DNA unless the proper restriction modification
pattern (i.e. methylation pattern o f DNA) is present (19, 36, 169). Not only is this
methylation pattern species specific, but it is also strain specific (169). A method outlined
by Donahue et al (36) was adapted for use in C. jejuni to methylate the plasmid
containing the disrupted cj1427c gene so that the restriction modification signature
unique to C. jejuni ATCC 700819 would be present. Following this, transformation was
easily achievable using both natural transformation, in which the plasmid was simply
mixed with bacteria, or electroporation.
To verify the correct insertion o f the disruption construct in potential
transformants, colony PCR was conducted. Using primers specific for cj1427c, a shift in
the size o f the gene fragment was observed, indicating that the wild type cj1427c gene
had been replaced with the chloramphenicol disrupted gene via homologous
recombination (Figure 4A). Further confirmatory PCR was done to verify the
recombination. Amplifying the region between the cjl427c and cjl426c genes (primers
1427 RT Top, annealing upstream o f the chloramphenicol resistance cassette and 1426
RT Btm; see appendix for primer sequences), a shift compared to wild type was observed,
corresponding to the presence of the chloramphenicol resistance cassette (Figure 4B).
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Similarly, amplifying the area between cjl427c and cjl425c (1427 RT Top and 1425 RT
Btm, respectively) yielded a shift in size corresponding to the presence o f the
chloramphenicol resistance cassette in the potential transformants. Finally, when the
region between cj1426c and cj1425c (1426 RT Top and 1425 RT Btm, respectively) was
amplified, no difference was observed for the fragment when comparing the potential

cjl427::CAT transformant to wild type, as the amplified region does not contain the
chloramphenicol resistance cassette.
In order to ensure that a double homologous recombination event occurred while
constructing the new cjl427::CAT mutant, a fragment from cjl428c to cjl426c (primers
1428 RT Top and 1426 RT Btm, respectively) was amplified (Figure 4C). An increase in
size o f the amplified fragment from the c jl427:: CAT mutant corresponds to the insertion
o f the chloramphenicol resistance cassette.
As shown previously, the cjl427::CATA mutant possesses a large deletion, up to
and including cjl421c. To verify that the same error did not occur in the new

cjl427\:CAT transformants, a fragment from cj1425c to cjl418c (primers 1425 RT Top
and Cj 1418P1, respectively) was amplified. No difference was observed between wild
type and cj1427wCAT, indicating that no gene deletion event occurred in the

cjl427::CAT mutant (Figure 4D). DNA sequencing was also conducted to verify the
correct construction o f the new cjl427::CAT mutant. Sequencing at the junction where a
large deletion o f the C. jejuni genome occurred in the cjl427::C AT A mutant revealed that
there was no such deletion in the newly constructed cjl427v.CAT mutant.
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Figure 4. Characterization of the new cjl427::CAT mutant via PCR.
In all panels, a schematic shows the region of the C. jejuni genome that was amplified; small arrows above
and below the genome represent the primers that were used. The box within the cj1427c gene represents
the chloramphenicol resistance cassette that was inserted. An inset table shows the sizes of the expected
PCR products for both the wild type and the cjl427::CAT mutant strain. In panels B, C and D, a
representative colony of the cjl427::CAT transformants is shown. Similar results were observed for other
potential transformants that were screened via PCR. A) Colony PCR screen of the potential
cjl427::CAT mutants. Colony PCR of the clones reveals that they all possess a larger cj1427c gene,
corresponding to the insertion of the chloramphenicol resistance cassette. Numbers at the top indicate the
various transformants screened. P = pET1427 CAT::Coli plasmid was run to ensure no potential
degradation of the plasmid occurred. The three bands represent the supercoiled, coiled and linear forms of
the plasmid. B) The cjl427::CAT mutant possesses the disrupted cjl427c gene and does not have any
further deletions. PCR of the regions between cj1427c and cj1426c and cj1425c and cj1427c show a size
increase in the cjl427v.CAT mutant, corresponding to the expected size increase due to the insertion of a
chloramphenicol resistance cassette. The region between cj1425c and cj1426c does not show a size
difference for the cjl427v.CAl mutant compared to wild type, as expected. C) The region upstream of
cjl427c is not deleted in the cjl427::CAT mutant PCR of the region between cj1428c and cj1426c
shows a size increase in the cjl427::CAT mutant corresponding to the expected size increase due to the
insertion of a chloramphenicol resistance cassette. Black triangles indicate the relative amounts of DNA
template used for PCR reactions D) The region between cj1425c and cj1418c is not deleted in the
cjl427:iCAT mutant PCR of the region between cj1425c and cj1418c shows no difference in size
compared to wild type. This indicates that no gene deletion is present in the new cjl427::CAT mutant.
Parts of the C. jejuni genome are not shown, and are represented by a double slash (//). Black triangles
indicate the relative amounts of DNA template used for PCR reactions.
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3.1.4

Determination of gene transcription in the wild type and mutant strains
via reverse transcription and quantification via real-time PCR
Real-time PGR was used to investigate the expression levels o f the genes involved

in capsule synthesis and modification. Previous work has shown that the C. jejuni
capsular cluster possesses significant sequence similarity to CPS biosynthesis genes for
group II and group III CPS o f E. coli, whereby the capsular region is flanked by
conserved genes encoding proteins involved in the transport o f the CPS (84,173). It is
thought that a single promoter controls the genes within the capsular cluster, and as a
result, expression o f these genes would be at similar levels, or perhaps with decreasing
levels proportional to the distance from the capsular promoter (175). In addition, RT-PCR
was used to test whether the inactivation o f the heptose modification pathway via the
insertion o f an antibiotic resistance cassette would have any feedback regulatory effects
on the production or export o f other CPS components.
To reach meaningful comparisons between gene expression levels, each gene
must first be normalized to an internal housekeeping gene. For intrastrain comparisons,
differences in gene expression levels were considered significant if they were greater than
5 times or less than 1/5 the level, respectively, when compared to the housekeeping gene
(cj1537c). For interstrain comparisons, differences in gene expression levels were
considered significant if they were greater than 5 times or less than 1/5 the level found in
the wild type strain, respectively.
Throughout the calculation o f differences in gene expression, primer efficiencies
must also be taken into consideration. Primer efficiency is defined as the ability of a
primer pair to amplify a given template under specific conditions. Primer pairs may differ
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in their ability to amplify their respective products. As a consequence, if primer
efficiency was not taken into account, then apparent alterations in gene expression could
have been due to differences in cDNA amplification and not to differences in the cDNA
levels themselves. When calculating the relative gene expression for each gene, the
primer efficiencies for each primer set were taken into account using the Pfaffl method.
This method determines the expression ratio between two genes (i.e. gene of interest and
the reference (housekeeping) gene) in which the efficiencies o f the two primer pairs are

i

different.
Several large differences were observed when comparing the expression o f each
gene relative to the housekeeping gene within each strain (Figure 5A). Low levels of
transcripts were detected for kpsM and the gene immediately downstream, cj1447c.
Throughout our studies, the expression levels o f kpsM were extremely low, making it
difficult to quantitate. The downstream gene cjl445c had a level o f transcription
comparable to other genes within the capsular cluster. Similarly, cj1430c and cj1429c had
very low levels o f detected transcript, while cj1428c and downstream genes showed
levels o f transcription comparable to the other genes within the capsular cluster. This
pattern holds true for all the strains for which RT-PCR data were gathered.
Another objective o f the RT-PCR study was to ensure that the genes that were
downstream o f the inserted antibiotic resistance cassettes were non-polar. To do this, the
data from Figure 5A (levels o f gene expression relative to an internal housekeeping
gene) in each strain were taken as a ratio over the respective genes in the wild type strain

(Figure 5B, interstrain comparison).

j
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The genes that were directly downstream o f the chloramphenicol resistance
cassette in cj!427\:CAT and cj!428::CAT showed similar levels o f transcription
compared to wild type, indicating that the insertion o f the antibiotic resistance cassette
was non-polar (Figure 5B). In the cj!430::CAT mutant, cj1429c is directly downstream
o f the chloramphenicol resistance cassette. This gene showed significant upregulation,
but this upregulation is not due to polarity effects o f the chloramphenicol resistance
cassette, as previously demonstrated in the cjl427v.CAT and cjl428::CAT strains. More
likely, the upregulation in cj1429c is due to a feedback regulatory effect o f inactivating

cjl430c. This upregulation in cjl429c was also observed in the cjl428\\CAT mutant,
indicating that the loss of either cj1430c or cjl428c likely generates feedback where, as a
result, cj1429c expression is significantly upregulated. This same mechanism may also
explain why in cjl428::CAT and cjl430::CAT, expression o f the cjl426c gene was
slightly upregulated. In KpsM, similar to the other mutants in our collection, the gene
directly downstream o f the kanamycin resistance cassette had levels o f transcription
comparable to the wild type, also indicating that the insertion o f this cassette was non
polar.

O“'
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Figure 5. Real-time PCR data in wild type and mutant strains of C jejuni for genes
within the capsular cluster.
Due to the naming nomenclature o f the genes in the capsular cluster, a cj!446c gene is
not present. Large Xs in cjl427::CATA indicate deletions in the particular genes.
Additional genes that are also deleted as previously elucidated are not shown. Diagonal
lines (//) indicate genes between cj1430c and cj1444c, exclusive, were not analyzed.
Bolded arrows indicate potential cryptic promoter sites. G = Chloramphenicol resistance
cassette. K = Kanamycin resistance cassette. N/A = not applicable A) Intrastrain RT-

PGR data for wild type and mutant strains. Expression levels for the genes tested are
shown, relative to the internal housekeeping gene {cj1537c). Due to very low levels of
transcript for the kpsM gene, absolute numbers cannot be presented. As a result, ND
indicates none detected. B) Interstrain RT-PCR data for mutant strains. The relative
gene expression levels for the genes tested are shown, taken as a ratio to the respective
genes in the wild type strain. As the absolute transcript abundance for kpsM was not
determined in A), absolute numbers cannot be presented. Instead, a ++ indicates a much
higher level o f expression relative to wild type, a - indicates a lower level o f expression
relative to wild type, while a 1.0 represents a level o f transcription similar to wild type
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2.4+/-0.2

1.8+/-0.6 3.9+/-0.7

03+/-1.0

1.6+/-1.0 0.6+/-1.0 0.9+/-0.4

N/A
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3.2

THE EXAMINATION OF CPS CHARACTERISTICS

3.2.1

Involvement of cjl427c, cj!428c, cj!430c, and kpsM in capsular synthesis
To determine the role o f the genes o f interest in CPS biosynthesis, CPS of the

wild type, cjl427::CAT, cjl428::C AT, cj1430::CAT, KpsM and cj142 7::CAT A mutants
were extracted using an adapted hot water/phenol method (171). This method offers
significant advantages over a crude SDS solubilization (68) as near complete removal of
proteins and most LOS from aqueous solutions can be achieved. Several rounds o f
extraction are conducted to obtain the maximal yield o f CPS material. In addition, an
ultracentrifugation step is important in pelleting the majority o f the LOS contamination.
McNally et al have shown that a disruption of the cjl428c gene led to a loss o f the
modified heptose side-branch, leaving a mutant whose CPS was unbranched (153). It was
o f interest to determine whether inactivation o f other heptose modification genes, namely

cj1427c and cj143 Oc, also led to the lack o f a modified heptose side-branch.
Samples were analyzed by SDS-PAGE on 7 cm gels and subsequent silver
staining (Figure 6A). High molecular weight species were observed in the wild type
lanes, indicative o f CPS. Similarly, high molecular weight species were observed for the

cj!427::CAT, cjl428::CAT and cjl427wCATA mutants. This indicates that despite the
loss o f a heptose modification gene, these mutants are still able to produce CPS. The

cjl427::CATA mutant is still able to produce a CPS, despite the fact that it has a large
portion o f CPS related genes deleted. The bands observed in these mutants ran slower
than those o f the wild type, indicating that the CPS composition or structure is altered by
the gene disruption. Interestingly, the cjl430::CAT mutant showed a strikingly different
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CPS profile than the other mutants, with less CPS produced overall. In addition, the
banding pattern o f the CPS is significantly different, suggesting that the structure of the
CPS is altered. The KpsM mutant, in contrast to expectations, showed some degree of
staining near the top o f the gel; this was thought to be either background staining or high
molecular weight material corresponding to the presence o f CPS.
To gain more resolution into the CPS o f the wild type and mutants and to resolve
the potential high molecular weight material observed in the KpsM strain, a larger, 13 cm
SDS-PAGE gel was used for analysis (Figure 6B). This larger format gel offers excellent
resolution o f the capsule and is desirable for enhancing the banding pattern characteristic
o f the repeating sugar units that comprise the CPS. With this increase in, resolution, the
banding pattern o f the CPS for the wild type, c jl427:‘.CAT, c jl428::CAT and
cjl4 2 7::CATA mutants became evident. It is clear that CPS synthesis is tightly regulated
in the wild type and the mutant strains, as silver staining shows very regular spacing of
the bands. Interestingly, the cjl427::CAT and cj!428::CAT mutants displayed a wider
variety o f CPS species; CPS molecules o f higher and lower molecular weight molecules
are present compared to wild type CPS. In contrast, thé cjl427::C AT A mutant showed
fewer bands than the wild type, indicating that regulation o f capsular chain elongation
may be disrupted, resulting in fewer species o f CPS with multiple sugar units. The
cjl430::C AT mutant again shows a significantly different CPS staining pattern than the
other mutants. With the increase in resolution using a 13 cm gel, the KpsM mutant shows
the presence o f high molecular weight material, apparent as a smeary pattern, suggesting
the presence o f CPS.
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Figure 6. Silver staining of wild type and various C. jejuni mutants
Bracketed areas indicate the high molecular weight species thought to be CPS, and the
lower molecular weight species thought to be LOS. The relative volumes o f each sample
loaded are indicated by the triangles. Three dilutions were used so that comparisons
between each strain could be made. MW = molecular weight marker. The sizes o f the
proteins standard in kilodaltons are indicated to the left o f the gel. A) Silver stain of the

CPS in wild type and mutant strains on 7 cm SDS-PAGE gels. Due to the small size
o f the gel, CPS bands appear as a smear o f high molecular weight molecules. Noticeable
differences were observed for the mutants’ CPS, especially for the cjl430\\CAT mutant.

B) Silver stain of the CPS in wild type and mutant strains on 13 cm SDS-PAGE gel.
To gain more resolution, a 13 cm SDS-PAGE gel was used. This gel offers more
resolution than the 7 cm gels, and the banding nature o f CPS is well resolved in all strains.
Similar observations as in A) were made regarding the capsular staining patterns.
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3.2.2

Purification of C. jejuni CPS from wild type and mutants
The structure o f C. jejuni ATCC 700819 LOS has been elucidated (158), and it is

known that it contains a heptose. Purified CPS samples with no LOS are desirable, as the
heptose that may be liberated from LOS could contaminate downstream nuclear magnetic
resonance (NMR) analysis. As the purpose o f our research is to investigate modified
heptoses that are part of the CPS, the presence o f heptoses from other sources could
confound NMR analysis, resulting in erroneous conclusions. To remove as much LOS as
possible, the aqueous phase was ultracentrifuged to pellet LOS, while the CPS o f interest
remained in the supernatant. Any contaminating proteins left from the hot water/phenol
purification were removed with Proteinase K. The amount of Proteinase K was optimized
to ensure that a minimal amount remained after this treatment. The absence o f a 30 kDa
band, corresponding to Proteinase K, was verified via silver staining (Figure 6A, B). The
final result o f this adapted hot water/phenol method are samples that are highly enriched
in CPS, free o f proteins, and relatively free o f LOS.
However, despite the hot water/phenol purification method, LOS was still found
in the samples (Figure 6A, B). Size exclusion chromatography was used in an attempt to
remove the LOS, using a gel matrix with a fractionation range o f 1000 - 6000 Da.
Smaller molecules such as LOS would be retained within the matrix, while larger CPS
molecules would not, and should be found in the void volume. Fractions were collected,
and then run on SDS-PAGE gels and silver stained; however, it was found that the gel
matrix failed to separate the LOS from the CPS as fractions containing the CPS of
interest also showed traces o f LOS (Figure 7A).

IS
In addition to size exclusion chromatography, another method of removing LOS
from mixed LOS and CPS samples was attempted using the method outlined by Aspinall
et al (10). In this method, LOS molecules were chemically cleaved at the linkage between
the lipid A anchor and the Kdo sugar using acetic acid. It was thought that this procedure
would reduce the size o f the LOS molecules due to the loss o f the lipid A anchor,
allowing the remaining fragment to be retained by the column matrix. However, it was
observed that while acid treatment reduced the amount o f LOS present in the samples
(compare Figure 7B, lane 1 and lane 2, before and after acetic acid treatment,
respectively), it did not separate the LOS away from CPS (see fractions 51 and 54).
An ammonium acetate treatment was also conducted to compare, the effect o f a
milder acid treatment on LOS (Figure 7C). This treatment potentially had an effect on
separating LOS from CPS based on the fact that early fractions showed high molecular
weight species, indicative o f CPS, while later fractions showed low molecular weight
species, indicative o f LOS (Figure 7C). However, a tricine gradient gel showed that there
was no LOS degradation after this treatment (Figure 7D, compare lanes 1 and 4, before
and after ammonium acetate treatment, respectively).

'

Gu andTsai (53) reported that lipopolysaccharide in Neisserial species were able
to be purified away from outer membrane vesicles using sodium deoxycholate. As a
■o

similar effect is desired for C. jejuni, where LOS separation from CPS is desired, the
methodology was adapted and used. While this method failed at achieving the initial goal
o f separating LOS from CPS, there was an unexpected effect o f sharpening the resolution
o f the CPS bands (Figure 7E). The reason for this enhancement o f the banding pattern o f
the CPS is unknown at this time.
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Figure 7. Various methods of purification were attempted to purify LOS away from
CPS.
In panels B through E, - and + symbols represent samples that were mock treated or
chemically treated, respectively. In all panels, samples were fractionated using size
exclusion chromatography, using various gel matrices (panels A - D, Biorad Biogel P-6:
fractionation range 1000 - 6000 Da; panel E, Sigma-Aldrich Sephadex G50: fractionation
range: 500 - 10000 Da). Numbers above each lane represent the fraction number,
corresponding to the nth milliliter o f the flow through. LOS and CPS regions o f interest
are bracketed. A) Silver stain of samples separated by size exclusion chromatography.
Co-elution o f both CPS and LOS occurred, resulting in a failure to separate the LOS from
CPS. B) Acetic acid treatment of CPS samples degrades LOS. The acetic acid
treatment degraded LOS, to some degree, without degrading CPS. However, this
treatment failed to separate the LOS and CPS molecules. Due to the large concentration
o f LOS in the.non-treated samples, the LOS stains negatively. C) A mild ammonium

acetate treatment appears to separate CPS from LOS. Fractions 19 - 28 contained
CPS while fractions 46 - 52 contained LOS, indicating that the ammonium acetate
treatment may have worked to separate the two molecules. D) Tricine gradient gel

analysis of ammonium acetate treated samples. Analysis by tricine gradient gel
analysis shows that ammonium acetate treatment in D) had no effect on LOS as initially
hypothesized, as there was no difference in mock treated and ammonium acetate treated
samples. A <j) indicates an empty lane. E) Sodium deoxycholate fails to separate LOS

from CPS. Sodium deoxycholate did not allow for the separation o f LOS from CPS, but
had the unexpected effect of sharpening the resolution o f CPS banding.

80

B)
Acetic Acetic
Acid- Acid +
Before
Column

48

51

54

57

60

63

66

CPS

LOS

81

D)
NH40AcBefore
Column d>

NH40Ac+
Pooled Pooled
Before
Fractions Fractions
Column <l> 15-18
20-36

Pooled
Fractions
48-52

E)
NaDOC- NaDOC+
Before Before
Column Column 60

64

68

72

76

. 80

84

88

y

cps

LOS

82

3.2.3

CPS elucidation of the wild type and mutant strains
Despite efforts to purify contaminating LOS away from CPS, success was not met,

and ultracentrifuged purified samples (without any further treatment) were sent for
compositional characterization. Approximately 10 L o f each strain o f C. jejuni were
grown up in liquid media and subjected to hot water/phenol purification as summarized
in section 2.19.
Several interesting observations were made from the results (Table 1). First, it
was observed that the wild type possessed heptose in the CPS, as expected. Similar to the
findings o f St. Michael (153), disruptions in cj1427c, cj1428c and cj1430c led to a lack of
a heptose in the capsule. While this precludes us from assigning a precise biochemical
function to each o f the mutated genes, it confirms that the disrupted genes are indeed
involved in heptose modification.
Second, the wild type strain contains no phosphoramidate molecule. This is
intriguing, as it is thought that the phosphoramidate moiety is a side-branch o f the ATCC
700819 capsule (113). The c jl427::CATA mutant does not possess a phosphoramidate
side-branch; this is expected, as the genes that are responsible for transferring the
phosphoramidate molecule to the main capsular backbone (cj1422c and cjl 421c) have
been deleted, as previously confirmed in section 3.1.2. For the other mutants, either a
trace, or the positive presence o f phosphoramidate was confirmed.
It is also worth noting that while the wild type strain possesses an ethanolamine
on glucuronic acid, the mutants possessed either ethanolamine or 2-amino-2deoxyglycerol (GroN). It has been previously shown for C. jejuni ATCC 700819 that
phenotypic variants are present in a population, despite being grown under the same
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substituents on the glucuronic acid moiety.
Sugar analysis data were also obtained via acid hydrolysis; all results were
normalized to galactosamine (GalN), a break down product o f N-acetyl galactosamine
(GalNAc), which is one o f the three sugars that make up the repeating trio o f sugars in
the main capsular backbone o f C. jejuni ATCC 700819 (114). It was observed that there
were varying levels o f ribose in each mutant, as well as trace amounts o f galactose.
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Table 1. Summary of NMR results for wild type and mutant C. jejuni strains.
Sugar analysis data was conducted using anion-exchange chromatography after full acid
hydrolysis. Numbers in the columns under “Sugar analysis data” represent the amounts of
various sugars present, after normalization to GalN. A plus (+) or minus (-) in the NMR
spectroscopy data columns represent either the presence or the absence o f the specified
molecule, respectively. GalN = galactosamine. Rib = ribose. Gal = galactose. Hep =
heptose. Me = methyl. MeOPN = phosphoramidate. GalNAc = N-acetyl galactosamine.
GlcA = glucuronic acid. EtN = ethanolamine. GroN = 2-amino-2-deoxyglycerol.

Sugar analysis
data
GalN Rib Gal
WT
cj1427v.CAT
cjl428:: CAT
cjl430::CAT
cjl427::CATA
KpsM

1
1
1
1
1
1

2.6
1.2
3.6
1.4
0.9
2.7

0.1
trace
0.15
0.18
trace
trace

NMR spectroscopy data
Hep
+
-

:

8,9-Me2
on Hep
+
■- ■

-

-

-

MeOPN on
GalNAc
. ■"+.
trace
+
-

Not analyzed

Substituent on
GlcA
EtN
EtN, GroN
EtN, GroN
EtN, GroN
EtN, GroN
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Figure 8. The growth rate of the cjl427::CAT mutant is greater than the wild type.
Growth rate experiments were conducted over a period o f 24 hours. Density was
measured in Klett units. Results shown are the mean and standard errors from three
independent experiments. Between 3 and 8 hours, the c jl427:: CAT mutant was found to
grow significantly faster than the wild type indicating it had less o f an initial lag phase.
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Effect of gene disruption on bile salt resistance
C. jejuni has been shown to be resistant to bile salts in the intestine (105, 106). In

addition, CPS has also been shown to be involved in resistance to bile salts in other Gram
negative bacteria (14,129). Our laboratory previously found that at low concentrations of
bile salts, all mutants behaved similarly to the wild type in that little effect was observed
(100). At higher concentrations o f bile salts, the cji427::CATA and KpsM mutants were
no more susceptible than wild type. However, the cjl428\\CAT and cjl430::CAT mutant
were more resistant to bile salts than the wild type. As it has been determined that the

cjl427:\CAT, cjl428\\CAT and cjl430::CAT mutants lack a heptose in the CPS, it was
\
thought that the previously uncharacterized cjl427::CAT mutant would behave similarly
to the other mutants in terms o f bile salt sensitivity. The cjl427:\CAT mutant was
exposed to increasing concentrations o f a mixture o f cholate and deoxycholate salts, two
components o f bile. At concentrations up to 0.25 g/L, the bile salts had little effect on the
wild type and the cjl427::CAT mutant. However, at higher concentrations, both the wild
type and the cj!427::CAT mutant showed very similar susceptibility to bile salts (Figure
9), contrasting the findings that were previously found for the cjl428::CAT and

cj!430::CAT mutants.

t
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Figure 9. Susceptibility of wild type and the cjl427::CAT mutant to bile salts.
Both the wild type and the cjl427::CAT mutant were exposed to varying concentrations
o f bile salts for 15 minutes at 37°C before being serially diluted and plated for CFU
counts. Results shown are the mean and standard errors from 3 independent experiments.
Both strains showed extremely similar patterns o f susceptibility to bile salts. At low
concentrations o f bile salts, both strains show little susceptibility. At higher
concentrations, both strains are susceptible.
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3.3.3

Effect of gene disruption on SDS resistance
To determine whether C. jejuni susceptibility to bile salts was detergent specific,

sodium dodecyl sulfate (SDS) susceptibility was also investigated. No significant
difference was found between the wild type and the cjl427:\CKY mutant in terms of
susceptibility to SDS (Figure 10). This result is similar to what has been previously
observed by our laboratory for the other compositional mutants (100).
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Figure 10. Susceptibility of wild type and c/7427::CAT mutant to SDS.
The wild type and c jl427::CAT mutant were exposed to varying concentrations o f SDS
for 15 hours at 37°C under microaerophilic conditions with shaking to determine their
susceptibility. Results shown are the mean and standard errors from two independent
experiments. No significant difference was observed between the wild type and the
c jl427::CAT mutant. With increasing SDS concentrations, more bacteria were killed.
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3.3.4

Effect of gene disruption on serum resistance
It has been previously shown that CPS plays a role in serum resistance in other

Gram negative bacteria (13, 32, 62, 139, 144). In addition, our laboratory has
demonstrated that a capsuleless KpsM mutant is killed extremely effectively by serum,
even at low percentages (5%) (100). This shows that the capsule o f strain ATCC 700819
is essential in conveying serum resistance. We have also shown that the cjl427::CATA
mutant behaved very similarly to the KpsM mutant, in that it was killed very quickly
indicating that the phosphoramidate and the heptose side-branches may have some role in
conferring serum resistance. In contrast, the cjl428::CAT and cjl430::CAT mutants
showed slightly more resistance than the KpsM and cj!427::CATA mutants, but were
overall, more susceptible to serum than wild type. To determine the susceptibility o f the

cjl427::CAT mutant to serum, it was exposed to varying concentrations. At 20% serum,
the wild type strain exhibited resistance and was only partially killed when exposed

(Figure 11 A), agreeing with our previous findings. This value represents the point where
more than 50% o f the bacteria have been killed (LD5 0 ). In contrast, the cjl42 7::CAT
mutant, despite having the same capsular composition as the cjl428::CAT and

cjl430::CAT mutants, showed extremely high susceptibility to serum, even at
concentrations as low as 10%. To determine whether changes in serum resistance were
due to differences in the rate o f killing, the wild type and cjl427::CAT mutant were
exposed to 20% serum over a period o f 90 minutes. At this percentage, a significant
difference in terms o f viability was observed for the wild type and the cjl427::CAT
mutant even after only 15 minutes (Figure 11B). By the end of the timecourse

experiment, the c jl427:\CAT mutant showed almost complete death, corresponding to
the results found in Figure 11A.
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Figure 11. Assessing the susceptibility of wild type C. jejuni and the cjl427::C A T
mutant to serum.
A) The cjl427::CAT mutant shows extremely high susceptibility to serum. After
incubation with varying serum concentrations for 1.5 hours, the cjl427\:CAT mutant
showed extreme susceptibility to serum; even at low serum percentages (10%), the
mutant showed significant loss o f viability. At serum concentrations o f 20% and above,
no growth was observed based on CFU counts. B) The cjl427::C AT mutant dies faster

than wild type. A timecourse experiment using 20% serum shows that the cjl427::CAT
mutant shows much faster killing kinetics than the wild type strain; more than half the
bacteria are killed within the first 15 minutes. Results shown are the mean and standard
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3.3.5

Effect of gene disruption on autoagglutination
Previous work in our laboratory (100) showed that a capsuleless KpsM mutant

readily agglutinated over time, whereas the wild type bacteria did not. This was thought
to be due to the lack o f the capsule, exposing underlying adhesins. In contrast, the
cjl428:\CAT, cjl430::CAT, and cj!427::CATA mutant did not autoagglutinate,
indicating that a capsule likely is responsible for the lack o f autoagglutination. As the
cjl4 2 7 ::CAT capsule is structurally similar to that o f the other mutants, it was not
expected there would be any differences in agglutination compared to the wild type. As
expected, no significant difference was observed between the wild type and the
cjJ427::CAT over a three hour period (Figure 12).
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Figure 12. Autoagglutination assay comparing wild type and cjl427::CAT.
Both the wild type and the cjl427::CAT mutant were inoculated into sterile PBS in a
falcon tube and allowed to sit. Over the course o f three hours, the top portion o f the PBS
was carefully removed and the optical density measured to determine whether
autoagglutination was occurring. An unchanged optical density would indicate a lack o f
autoagglutination. Results shown are the mean and standard errors from three
independent experiments. No significant differences were observed for all timepoints
between the wild type and the cjl427::CAT mutant. The slight decrease in optical density
over the course o f three hours is due to the natural sedimentation o f the bacteria.
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3.3.6

Effect of gene disruption on motility

(52, 120, 176). As flagella and CPS are both anchored to the outer membrane o f the
bacteria, we sought to determine whether changes in the CPS due to disruption of the
putative heptose biosynthetic genes would affect motility. Motility assays were
conducted for the wild type and c jl427::CAT mutant. It was found that the c jl427v.CAX
mutant was less motile than the wild type strain when compared visually (Figure 13).
Previous work in our laboratory has also shown qualitatively that the cjl428::CAT,
cjl430::CAT, KpsM, and cjl427::CATA mutants had a decrease in motility, with the
KpsM mutant being completely non-motile. These data were verified quantitatively in
this thesis; the decrease in motility for all mutants was significant compared to the wild
type strain, with p values less than 0.05 (Table 2).
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Figure 13. Motility assay for wild type and the cjl427:iCAT mutant.
The cjl427::CAT mutant shows significantly less motility than wild type. Both wild type
and c/7427::CAT were stabbed onto a motility plate consisting o f 0.3% agar. Plates were
incubated for 48 hours before halos were measured. Shown in this figure is a
representative motility plate.
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Table 2. A quantitative comparison of motility for wild type and all mutant strains.
The motility o f the wild type and mutant strains were measured and compared
quantitatively after stabbing into 0.3% agar and incubation for 48 hours under
microaerophilic conditions. The values shown are for the diameters o f the motility halos,
measured in centimetres. The mean and standard errors (SE) o f three independent
experiments are shown for each strain. In addition, the p value, as determined by one-way
ANOVA, is shown. Compared to the wild type, all mutant strains were significantly
reduced in motility.

C. jejuni strain
WT
cjl427v. CAT
cj!428::CAT
cjl430:: CAT
cjl427::CATA
KpsM

Diameter of halo (cm) ± SE
3.09 ±0.09
2.35 ±0.08
2.77 ±0.06
2.73 ±0.06
2.38 ±0.10
0.00 ±0.00

p value
N/A
<0.01
<0.01
<0.01
<0.01
<0.01
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3.4

THE ROLE OF C. JEJUNI CPS ON THE INTERACTION WITH
VARIOUS CELL TYPES

3.4.1

Effect of gene disruption on adhesion and invasion of intestinal Caco-2
cells

It is known that the adhesion and invasion o f intestinal cells is important to the
virulence o f C. jejuni (17). It has been shown that the CPS o f C. jejuni strain 81-176 is
involved in this process (13). In addition, our laboratory has shown that in ATCC 700819,
a capsule is important in modulating the adhesion and invasion o f intestinal epithelial
cells (100). Our results showed that the capsuleless KpsM mutant had a very large
increase in adhesion and invasion; this was thought to be due to the exposure of
underlying surface adhesins, allowing the bacteria to invade more readily. Interestingly,
the cj!427::CATA mutant was also found to adhere to and invade Caco-2 cells slightly
more than the wild type, but not as much as the KpsM mutant, indicating that the lack of
the heptose and phosphoramidate molecules may facilitate adherence and subsequent
invasion (i.e. due to a lack o f steric hindrance o f underlying adhesins). In contrast, the

cjl428:\CAT and cj1420\\CAT mutants adhered to Caco-2 cells to the same level as the
wild type strain, but failed to invade.
Not surprisingly, the cjl427::CAT mutant behaved similarly to the wild type
strain in terms of adhesion to epithelial cells (Figure 14A). However, contrasting the

cj!428::CAT and cjl430::CAT mutants, there was no significant difference between the
cjl427::CAT mutant and wild type in terms of invasion of Caco-2 cells, as invasion,
albeit at low levels, was observed (Figure 14B). The very low levels of adhesion to and
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invasion of Caco-2 cells is consistent with what has been previously observed for the
wild type strain in the literature (39, 47, 157), as well as in our laboratory (100). Despite
these low levels of adhesion and invasion to epithelial cells, C. jejuni is still able to cause
disease.

Figure 14. Adhesion and invasion of wild type and cjl427::CArT C. jejuni to Caco-2
intestinal epithelial cells.
A schematic at the top of the panels indicate the experimental layout. Gm = gentamicin.
Results shown are the mean and standard deviation from two independent experiments.

A) Adhesion of wild type and cjl427:: CAT to Caco-2 cells. The cjl427::CAT mutant
behaved, very similarly to the wild type strain. Low levels of adhesion were observed for
both strains. No statistical significance was found. B) Invasion of Caco-2 cells by wild

type and the cjl427::CAT mutant. Both the wild type and the cjl427\\CAT were able
to invade Caco-2 cell, but at very low levels. No statistical significance was found.
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3.4.2

Effect of gene disruption on survival within macrophages
Recently, it has been shown that C. jejuni is able to survive within murine

macrophages (149). The precise mechanism for this ability is currently unknown, and as
such we wanted to investigate the effect that changes in the C. jejuni CPS would have on
survival within murine RAW 264.7 macrophages. Previous work in our laboratory was
conducted to investigate this phenomenon (100); however, due to the large variability
observed, it was necessary to carefully dissect C. jejuni-macrophage interactions.
To do this, macrophages were infected with either wild type or the mutant strains
of C. jejuni for two hours followed by a one hour gentamicin treatment to kill any
extracellular bacteria. The macrophages and bacteria were then incubated for various
timepoints before being lysed for CFU counts. As expected, the survival rate o f the wild
type and mutant strains decreased with prolonged duration within the macrophages

(Figure 15A). The cjl427::CAT and cjJ428::CAT mutants appeared to have a lower
number of recovered bacteria, even at the initial timepoint of the survival assay. To
investigate the killing kinetics of the bacteria by macrophages, it was necessary to
normalize the data in Figure 15A so that at the initial timepoint, the number of bacteria
that were alive within the macrophages (and thus able to contribute towards colony
forming units) were deemed to be 100 percent (Figure 15B). Interestingly, over the
timeline, the cjl427::CAT and cj!428::CAT mutants showed slower killing by
macrophages; however, this difference was deemed non-significant compared to the wild
type when a one-way ANOVA test was conducted. Results for the other mutants showed
similar killing kinetics to the wild type.

Figure 15. Percent survival of the wild type strain and mutant strains within
macrophages.
The survival rate o f wild type and the mutant strains was investigated over a time period
of three hours. Percent survival was calculated as the number of bacteria recovered from
macrophages divided by the number of bacteria recovered under the same growth
conditions, in the absence of macrophages. As the length of time post infection increases,
the number of bacteria able to survive decreases. Results shown are the mean and
standard errors from three independent experiments. The schematic at the top indicates
the experimental layout, where X represents the number of hours post infection. Gm =
gentamicin. A) Compared to wild type, the mutant strains have a lower survival rate

within macrophages. With the exception of the KpsM mutant, the other mutants
appeared to have a slightly lower rate o f survival within macrophages. However, there
was no statistical difference between the survival rates o f the wild type and the mutants
when a one-way ANOVA test was conducted with a p value cut off of 0.05. B) Some

mutants appear to have an increased ability to survive within macrophages
compared to WT. The data for each strain at timepoint zero in panel A) were normalized
to 100 percent survival. The cj!427::CAT and cjl428::CAT mutants appeared to be
killed less slowly than the other mutant strains, when compared to the wild type.
However, there was no statistical difference between the killing kinetics of the wild type
and the mutants when a one-way ANOVA was conducted.
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3.4.3

Effect of gene disruption on adhesion to macrophages

v

Upon analyzing data from survival within macrophages, subtle differences prior
to the survival testing were observed at timepoint zero between the wild type and mutant
strains o f C. jejuni. While this discrepancy was found to have a p value > 0.05, we
hypothesized phagocytosis or adhesion were responsible for these subtle differences. A
higher adhesion rate o f the wild type bacteria could explain why there was a higher initial
bacterial load within macrophages. Vice versa, a lower adhesion rate of the mutants
would explain the lower initial amount of bacteria within macrophages.
For the adhesion assay, both the wild type and mutant C. jejuni were incubated
with macrophages for 30 minutes at 4°C, a temperature known to inhibit phagocytosis
(180). This low temperature allows for any bacteria that interact with the macrophages to
be a result o f bacterial adhesion, and not as a result o f phagocytosis. Results indicate that
none of the mutants adhered significantly more or less to macrophages than the wild type
strain (Figure 16). The slightly higher adhesion rate o f the KpsM mutant may be
. . .
/
.
attributable to the loss of its capsule, exposing underlying adhesins, as previously
hypothesized by our laboratory (100).

Figure 16. Adhesion of the wild type and mutant strains to macrophages.
The adhesion rate of wild type and mutant strains o f C. jejuni to macrophages was
investigated. Percent adhesion was calculated as the number o f bacteria recovered from
macrophages divided by the number of bacteria recovered under thè same growth
conditions, in the absence of macrophages. A schematic at the top o f the figure represents
the experimental layout. Macrophages were exposed to bacteria for 30 minutes at 4°C to
allow for bacterial-macrophage interactions to occur before being lysed and plated for
CFU counts. Results shown are the mean and standard errors from three independent
experiments. No significant differences were found between the wild type and the
mutants when a one-way ANOVA test was conducted.

30 minutes at 4°C
— .... .——— — — | Lysis

Percent adhesion

WT
cj1427:: CAT
cj1428:\ CAT
cj1430:\CAT
cj1427::CATA
KpsM
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3.4.4

Effect of gene disruption on phagocytosis by macrophages.
A crucial aspect o f C. jejuni interactions with macrophages is phagocytosis. To

study phagocytosis of C. jejuni, macrophages were incubated with wild type and mutant
C. jejuni for various durations prior to the gentamicin treatment and subsequent lysis and
enumeration o f the bacteria via CFU counts. The increase in uptake o f the wild type
strain over time is intuitive; with a longer infection time, more bacteria are phiagocytosed
by macrophages (Figure 17). The mutant strains, with the exception o f the KpsM mutant,
showed similar degrees of phagocytosis by the macrophages over the same time period.
The higher phagocytic rate o f the KpsM mutant is likely due to the fact that this strain
autoagglutinates readily as previously demonstrated by our laboratory (100). This
detailed dissection o f the various steps involved in the infection pathway allowed us to
pinpoint the kinetics of C. jejuni interactions with host macrophages.

Figure 17. The uptake rate for the wild type but not the mutant strains increases
with time.
The phagocytosis of wild type and mutant C. jejuni strains into macrophages was
investigated over a period of four hours. Percent uptake was calculated as the number of
bacteria recovered from macrophages divided by the number of bacteria recovered under
the same growth conditions, in the absence of macrophages. The schematic at the top o f
this figure indicates the experimental layout, where X represents the infection time. Gm =
gentamicin. Results shown are the mean and standard errors from at least three
\
•
independent experiments. An increase in percent internalization for the wild type strain
was observed with longer infection times. The KpsM mutant was found to be
significantly different (p < 0.05) compared to the wild type at the same time point, as per
a one-way ANOVA, and is indicated by the asterisks (*).
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3.5

THE GENERATION AND GENETIC CHARACTERIZATION OF
COMPLEMENTED CPS MUTANTS

3.5.1

Complementation of disrupted genes via insertion into the 16S rRNA23S rRNA intergenic space region
To determine whether the observed phenotypes in the cjl427::CAT, cjl428::CAT

and cjl430::CAT mutants are gene specific, complementation must be carried out. The
intragenic spacer region between the 16S rRNA and 23 S rRNA genes o f C. jejuni was
chosen to facilitate integration into the genome. Three copies of these genes exist within
the C. jejuni genome, and complementation into one o f these regions will not affect
viability (87).
To construct the complementation constructs, gene splicing by overlap" extension
(gene SOE-ing) was employed. The complementation construct consists o f a por A
promoter, the gene o f interest to be complemented, followed by an antibiotic resistance
cassette. The

promoter was chosen as it is a highly active promoter for a porin

protein and will drive expression of the complementation construct. The antibiotic
resistance cassette will allow selection o f C. jejuni mutants that contain the
complementation construct, once transformants are obtained.
Gene SOE-ing of each construct to complement our mutants (cj!427::CAT,
cj!428::CAT, cj143O:\CAY m à KpsM) was done. As previously elucidated, the
cjl427:\C AT A mutant contains a large area of the genome deleted, and complementation
for this mutant was not attempted. Gene SOE-ing of each complementation construct was
successful; this was verified via PCR (Figure 18).
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The complementation constructs were inserted into a pBluescript vector
containing the 16S and 23 S rRNA regions of C. jejuni, constructed by Xuan Thanh Bui, a
PhD student in our laboratory. This plasmid was then mobilized into E. coli, and
transformants selected for and screened. The cjl427\:CAT, cjl428::CAT and

cjl430::CAT complementation constructs were successfully mobilized into E. coli, and
sequenced to ensure the constructs did not have any point mutations that could affect the
subsequent function o f the protein. Results showed that the cjl427::CAT and

cj!428::CAT mutants had single nucleotide polymorphisms (SNPs), while the
cjl430::CAT mutant did not. The SNPs in the cjl427::CAT mutant were found to be
deleterious and were fixed via QuikChange site directed mutagenesis. The SNPs in the

cjl428::QAT mutant resulted in amino acid changes that were determined to not affect
protein function.
At the

time

of submission

for

examination,

only the

cj!428::CAT

complementation construct was selectively methylated before mobilization into C. jejuni.
Screening o f the potential cjl428::CAT transformants was carried out using PCR; results
showed that the complementation construct was within C. jejuni (Figure 19A); however,
the complementation construct did not recombine into the 16S - 23 S rRNA area of
interest (Figure 19B). Further PCR screening also revealed that the complementation
construct did not integrate into either the cjl428c gene area or the porA promoter region

(Figure 19C and D, respectively). Despite this setback, this complemented mutant was
used in the phenotypic studies that were conducted to determine whether the previously
investigated phenotypes were gene specific.

Figure 18. Construction of the complementation constructs via gene SOE-ing.
PCR products showing the successful construction of each complementation mutant is
pictured. Each complementation construct was loaded in duplicate. A DNA ladder with
the corresponding sizes in kilobase pairs is shown on the left. A schematic shows the
primers and the area that was amplified via PCR. The inset table shows the expected sizes
for the complementation constructs.
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Figure 19. PCR screening of potential cjl428::CAT complement transformants in C.
jejuni.
In all panels, a schematic shows the area of interest that was amplified via PCR. An inset
table shows the expected sizes of the fragments. Numbers at the top o f each gel indicate
the various colonies screened. A) The cjl428:: CAT complementation construct was

successfully transformed into C. jejuni. A PCR showing the complementation construct
was successfully introduced into C. jejuni. KAN = kanamycin. Comp. plas. =
complementation plasmid B) The cjl428\: CAT complementation construct did not

integrate into the desired area. PCR using primers between the porA and 23 s rRNA
areas was carried out. The lack of a band indicates that the complementation construct
did not integrate into the desired area. KAN = kanamycin. Comp = complementation C)

The cjl428:: CAT complementation construct did not integrate into the cjl428c gene
area. PCR showed that the complementation construct did not integrate into the cj1428c
gene within the capsular cluster, as a band corresponding to the chloramphenicol
disrupted cj1428c gene only was observed in all potential transformants. The box within
the cjl428c gene represents the chloramphenicol antibiotic resistance cassette. Chr =
chromosomal. D) The cjl428::CAT complementation construct did not integrate into

the porA promoter region. PCR shows that the complementation construct did not
integrate into the porA gene within the C. jejuni genome, as bands o f the size
corresponding to the wild type porA gene size were observed in all potential
transformants.
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3.5.2

Evidence that the complemented cjl428::CArY mutant produces the
cjl428c gene product
Surprisingly, the c jl428::CAT complementation construct did not integrate into

the 16S - 23S rRNA region as desired, and to investigate whether the cjl428c gene
product was being produced, total cell lysate was run on an SDS-PAGE gel. Compared to
the wild type, the cjl428::CAT mutant did not have a band of the expected size, while the
complemented cj!428::C AT mutant had a band of the expected size, indicating that
Cj 1428c was being produced. The higher level that was observed in the complemented
c jl428:: CAT mutant is likely due to the highly active porA promoter that is part of the
complementation construct.

Figure 20. Coomassie staining of total proteins shows that the cjl428c gene product
is being produced in the complemented cj!428::CAT mutant.
Total proteins o f the WT, cj'1428::CAT and complemented cjl428::CAT strains were run
on an SDS-PAGE gel. The relative amounts loaded are indicated by the black triangles.
The calculated size o f the cj1428c gene product was 39.4 kDa. Bands o f the expected size
were observed in the WT and the complemented cjl428::CAT mutant (boxed), and was
absent in the cjl428::C AT mutant. The higher levels o f expression o f the cj1428c gene
product in the complemented cjl428::CAT mutant is likely due to the higher activity o f
the porA promoter.
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3.5.3

Analysis of the complemented c jl4 2 8 ::CAT mutant phenotypes
Despite the cjl428::CAT complementation construct not recombining into the

16S - 23 S rRNA region that was desired, studies were carried out to determine whether
the phenotypes which previously showed significant differences compared to wild type
could be complemented. Restoration o f the phenotypes in the complemented
cjl428::CAT mutant would indicate gene specificity.
Motility assays were conducted for the cjl428:\CAT and complemented
cjl428::CAT strains. Interestingly, the complemented cjl428::CAT mutant showed less
motility than the cjl428::CAT mutant and the wild type (Figure 21); these data were also
verified quantitatively (Table 3). The complemented cj'1428::CAT mutant was found to
be significantly reduced in motility compared to the wild type and the cjl428::CAT
mutant strain when a one-way ANOVA was conducted (p < 0.05).
In addition to motility, survival within macrophages (Figure 22) and the
phagocytic uptake by macrophages (Figure 23) for the complemented cjl428::CAT
strain were investigated. The cjl428::CAT mutant was conducted in parallel to serve as
an internal control. In terms o f survival, all strains showed a decrease in survival with
increasing time. The cjl428::CAT showed a lower survival rate within macrophages, but
similar, or slightly slower killing kinetics compared to the wild type strain. The
complemented cjl428::CAT mutant showed a significant increase in survival compared
to the cj!428::CAT mutant and at levels similar to wild type at three timepoints,
indicating that partial complementation occurred. A significantly slower killing of the
complemented cj1428::CAT mutant was observed at one timepoint. This result cannot be
rationalized at this time, and will require re-visiting in the future.
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For phagocytic uptake by macrophages, as observed previously, an increase in
uptake occurred with an increase in infection time for the wild type strain. The
cjl428::CAT strain was phagocytosed poorly by macrophages, and an increase in uptake
was not observed until longer durations o f infection were used. The phagocytosis rate of
the complemented cjl428::C AT mutant appeared to be similar to that of the wild type.
When comparisons between the cjl428::CAT mutant and the complemented
cjl428:\CAT mutant were made as per a one-way ANOVA, there was no significant
difference found between the two, except at the first timepoint. This suggests that only
partial complementation o f the cjl428\: CAT mutant occurred.

Figure 21. Motility assay for wild type, cjl428::CAT and complemented
cjl428::CAT mutant.

The motility o f the wild type, cjl428::CAT and complemented cjl428::CAT strains were
measured and compared after stabbing into 0.3% agar and incubation for 48 hours under
microaerophilic conditions. Plates were incubated for 48 hours before halos were
measured. Shown in this figure is a representative motility plate.
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Table 3. Quantitative assessment of the motility of the complemented cjl428::CAT
mutant.
The motility o f the wild type, cj!428::CAT and complemented cjl428\:CAT strains were
measured and compared quantitatively after stabbing into 0.3% agar and incubation for
48 hours under microaerophilic conditions. The values shown are for the diameters o f the
motility halos, measured in centimetres. The mean and standard errors (SE) o f three
independent experiments are shown for each strain. Compared to the wild type, the
cjl428::CAT and complemented cjl428::CAT mutants were significantly less motile.

C. jejuni strain
WT

cjl428::CAT
cj!428::C AT
complement

Diameter of halo
(cm) ± SE
3.10 ±0.10
1.90 ±0.06
1.20 ±0.05

p value
(compared to WT)

p value
(compared to cjl428::CAT)

N/A

N/A
N/A

<0.001
<0.001

<0.001

Figure 22. The ability of C. jejuni to survive in macrophages is partially restored in
the complemented cjl428::CAT strain.
The survival rate o f wild type, cjl428::CAT and complemented c jl428::CAT strain was
investigated over a time period o f three hours. The schematic at the top o f this figure
indicates the experimental layout, where X represents the number o f hours post infection.
Gm = gentamicin. Results shown are the mean and standard errors from three
independent experiments. As the length o f time post infection increases, the number o f
bacteria able to survive decreases. The complemented cjl428::C AT mutant’s ability to
survive within macrophages was restored to wild type levels, indicating complementation
occurred. A) Results are expressed as percent survival; CFUs o f bacteria exposed to
macrophages were taken as a ratio to the CFUs o f bacteria that were incubated under the
same conditions, with the exception o f not being exposed to macrophages. A one-way
ANOVA test showed that there was a significant difference between the survival rate of
the c jl428::CAT mutant and the complemented cjl428::CAT mutant, as indicated by the
asterisks (*). B) The data for each strain at timepoint zero in panel A) were normalized to
100 percent survival. Both the cj!428::CAT mutant and the complemented c jl428::CAT
strain were killed slower than the WT strain. At 1 hour post infection, a significantly
slower killing rate was observed between the wild type and the complemented
c jl428::CAT mutant, as indicated by the asterisk (*).

>Ho >Ho
4^

00

00

'3

Infection for 2 hrs Gm 1 hr Xhrs

CD

N>
4V

001

001

Time post infection (hrs)

y E llllllllllllllllllll

>
*<
u>
c/>*
u> Dl

** - ttttttti
Infection for 2 hrs Gm 1 hr Xhrs

*

Time post infection (hrs)

0
1

Percentsurvival
Percent survival

w

Figure 23. The internalization rate for the complemented cjl428::CAT mutant is
partially restored to wild type susceptible levels.
The internalization rate o f wild type, cjl428::CAT and complemented c jl428::CAT
strains in macrophages was investigated over a period o f four hours. Results are
expressed as percent internalization; CFUs o f bacteria exposed to macrophages were
taken as a ratio to the CFUs o f bacteria that were incubated under the same conditions,
with the exception o f not being exposed to macrophages. The schematic at the top o f this
figure indicates the experimental layout, where X represents the infection time. Gm =
gentamicin. Results shown are the mean and standard errors from three independent
experiments. For the wild type strain, with an increase in time the bacteria were allowed
to infect macrophages, an increase in percent internalization was observed. The
internalization rate of the complemented cjl428::C K l mutant was restored to wild type
levels, particularly when a 1 hour infection was conducted. At this timepoint, a
significant difference was observed between the c jl428::CAT mutant and the
cjl428::CAT complemented mutant, as indicated by the asterisk (*) (p < 0.05).
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CHAPTER 4 - DISCUSSION

4.1

Creation of a new cj!427::CAT mutant
It has been shown that the CPS present on the surface o f C. jejuni is involved in

the virulence o f strain ATCC 81-176 (13). Using structural data that was available for C.
jejuni ATC 700819, our laboratory has previously identified three gene targets in the CPS
biosynthesis cluster, cjl427c, cjl428c and cj!430c, that are putatively known to function
in the synthesis o f a modified heptose. To prove this, we have also previously constructed
cj1428c, cj1430c and KpsM antibiotic insertional knockout mutants. Unfortunately, a
cj1427c insertional mutant was not achieved, and to complete our panel o f mutants, a
cjl427c mutant was made as part o f the work in this thesis.
Prior attempts to create a cjl427c insertional mutant in our laboratory were
unsuccessful. RT-PCR data revealed that the genes cjl426c and cjl425c did not have any
level o f expression in the clones obtained indicating that a gene deletion event likely
occurred. Based on these data, PCR was carried out on areas flanking these two genes to
confirm that a gene deletion event occurred. It was shown that not only were cj1426c and
cjl425c deleted, but the area extending to, and including a portion o f cj1421c, was
deleted. This deletion was verified via DNA sequencing.
C. jejuni is known to have a genome sequence that possesses very few repeat
sequences (131). However, due to the initial method o f transforming C. jejuni via natural
transformation (19, 60, 167, 169), whereby the cjl427::CKY disruption construct was
ligated to genomic DNA, it is possible that introduction o f additional copies of
chromosomal DNA lead to homologous recombination in areas that were not o f interest.
It is likely that an unwanted homologous recombination event occurred during the initial
construction o f the cjl427::CATA mutant, resulting in the large deletion o f genes in the

-J
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capsular cluster. As mentioned previously, the deletion o f these genes results in a C.
jejuni CPS that is significantly altered in structure; not only is the capsule heptoseless,
but it is also free o f the side-branching phosphoramidate molecule. It has been previously
shown that the lack o f phosphoramidate on the CPS of C.jejuni causes attenuation in
virulence (27), and may explain the phenotypic differences that were previously
investigated for this mutant (100).
Due to the inability to control for unwanted homologous recombination events, a
method outlined by Donahue et al (36) was adapted and used for the creation o f a new
c jl427::CAT mutant. As the method involves site-specific and species-specific
methylation o f foreign plasmid DNA, the advantages are two-fold: 1) there will be no
unwanted homologous recombination as additional copies o f chromosomal DNA are not
being introduced into C. jejuni and 2) methylation o f the plasmid DNA will result in a
methylation signature that is unique to C. jejuni ATCC 700819, allowing for extremely
efficient transformation.
Following transformation o f wild type C. jejuni with the disruption construct, all
\

potential transformants were verified using conventional PCR and also DNA sequencing.
The resulting cjl427::CAT mutant is the one that has been used for all genetic and
phenotypic studies conducted in this thesis.

4.2

The expression levels of CPS related genes changes in response to gene
disruption
To investigate the transcription levels o f genes located downstream o f the

disrupted genes, RT-PCR was carried out. As expression levels o f genes can change
drastically depending on the life cycle o f the bacteria, a specific time point must be
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chosen to harvest the bacteria for RNA isolation. For this, we chose a timepoint 20 - 24
hours post inoculation as C. jejuni would be actively growing in the exponential phase,
and, based on previous experiments, expressing CPS (Figure 6A, B). This timepoint was
kept consistent for the harvesting o f RNA from all strains. In addition, this timepoint was
chosen as phenotypic studies conducted in this thesis were also conducted within the
same timeframe.
To gain a better understanding o f the expression levels o f the capsular cluster of
genes, RT-PCR was conducted for each strain in our possession. As mentioned
previously, the C. jejuni capsular cluster o f genes shows similarity to the one observed in
E. coli, and it was thought that a single promoter would control the. genes. It was
expected that the genes within the cluster would show similar levels o f expression, or
perhaps genes with greater distance from the promoter would show lower levels of
expression (175). However, against expectations, these data revealed that the level of
gene expression across the capsular cluster varied significantly. While most genes are
expressed at levels similar to the housekeeping gene, some genes (kpsM, cjl447c,
cjl430c, cj1429c) appeared to be expressed at lower levels, while cjl426c appeared to be
expressed at higher levels. KpsM is an autotransporter for capsule and Cj 1447c is a
probable capsule polysaccharide export ATP-binding molecule, so their low levels o f
expression may simply be due to a lack o f requirement for these catalytic enzymes to be
present in high quantities. As the downstream genes cj1445c and cjl444c are expressed at
levels comparable with other genes within the capsular cluster; this may be indicative o f
promoters that are present either in the intergenic areas between cjl447c and cjl445c or
possibly as part o f the end o f cjl447c. Similarly, cj1430c and cjl429c show very low
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levels o f expression, while downstream cjl428c shows levels comparable to the other
genes within the capsular cluster, again indicating the possibility o f promoter sequences
within the C. jejuni capsular cluster. To investigate this possibility, promoter prediction
software was used in an attempt to predict the location o f potential cryptic promoter sites.
However, currently available software was insufficient for our needs as the foundation o f
such prediction software is based on E. coli. This poses a problem as the C. jejuni -35
region was found to be different from the E. coli -35 region (175), and thus, software
prediction was not suitable. Future potential work may include the investigation o f these
cryptic promoters using a reporter gene system (i.e. lac system (177)) for analysis.
Alternative to the hypothesis o f cryptic promoters within the capsular cluster is
the possibility that the measured low levels o f expression could reflect the inherent
instability o f the RNA for these genes. It is known that differential mRNA degradation is
an important step in the regulation o f prokaryotic gene expression (93). KpsM and
Cj 1447c play a role in transporting CPS and acting as an ATPase, respectively. As these
enzymes would be catalytic in nature, it is possible that high levels o f these niRNA are
not required by C. jejuni, and as a result, additional mRNA is quickly degraded by the
cell.
Following the investigation o f the intrastrain gene expression, an interstrain
comparison was performed, whereby the expression levels o f the genes in each mutant
strain were taken as a ratio over the respective genes in the wild type strain. This was
done to determine whether the insertion of the antibiotic resistance cassette had polarity
effects on downstream genes. In general, it was found that genes immediately
downstream o f the resistance cassette in the mutant strains did not significantly differ
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from the expression levels o f the respective genes in the wild type strain. This is
consistent with the fact that the antibiotic resistance cassettes, by design, were non-polar.
Interestingly, in the cjl430::CAT mutant strain, the downstream cj1429c gene showed
highly significant upregulation compared to the same gene in the wild type strain. From
the other mutant strains in our collection, genes downstream o f the resistance cassette do
not show significant changes in expression levels and we can conclude the upregulation
o f cj1429c in cjl430::C AT is not due to polarity effects o f the chloramphenicol resistance
cassette. While cj1429c is part o f the C. jejuni capsular cluster (131), its function is
currently unknown. The phenotypes attributable to this gene will be further pursued by
our laboratory in the future using the same mutagenesis method that was used in this
thesis to study the effect o f the heptose modification genes.
Another observation from the RT-PCR data was that cj1426c was upregulated in
the mutant strains. The gene cj1426c is a putative methyltransferase and is hypothesized
to facilitate the transfer o f a methyl group to carbon 6 o f D-g/ycero-L-g/wco-heptose (61,
131). The capsular structure o f the wild type and mutant strains has been elucidated via
NMR, and based on the data, it was found that none o f the mutants produce a heptose. It
is puzzling that cjl426c is upregulated, as the molecule that requires méthylation is no
longer present in the capsule o f the mutants. It is possible that as a compensatory
mechanism, upregulation o f cj1426c occurs which results in an increase in the measured
levels o f expression. Precisely why this gene is upregulated is yet unknown, and may be
studied in the future.
The cjl427::CATA mutant was found to lack modified heptose and also the
phosphoramidate molecule. In this mutant, genes between cj1426c and cjl421c, inclusive,

have been deleted. Genes cjl423c -c jl4 2 6 c have been identified as being involved with
the synthesis o f the modified heptose precursor GUP-glycero-manno-heptosQ, while
genes cjl415c - cj1422c play a role in the production and transfer o f the 0-methyl
phosphoramidate group to the N-acetyl galactosamine o f the capsular backbone (112). As
the genes for the synthesis o f GDP-glycero-manno-heptose have been abolished, the
cjl427::CATA mutant will not only lack a modified heptose, but will also lack a normal,
non-modified heptose. In addition, cj 1421c function has been abolished in the
cjl427::CATA mutant, resulting in a linear capsule, free o f any side-branching molecules.
It is interesting to note that while synthesis o f GDF-glycero-manno-heptose has been
abolished, expression levels o f genes responsible for modifying heptose (cj1428c,
cj1430c) remain unchanged compared to levels in the wild type strain, indicating that
there is no feedback to repress the expression o f these genes. It is thus puzzling why the
disruption o f a single gene involved in heptose modification results in feedback within
the capsular cluster while deletion o f many genes does not.
As previously mentioned, with the exception o f the cjl42 7: :CATA mutant, which
possesses a capsule free o f any side-branching molecules, all other mutants show either a
trace or the positive confirmation o f phosphoramidate in the capsule, while the wild type
strain does not. In the future, it will be interesting to investigate phosphoramidate related
genes to determine possible upregulation of these genes in response to a lack of modified
heptose as a compensatory mechanism to decorate the capsule.

4.3

Disruption of cjl427c, cjl428c, and cjl430c affects CPS composition
The CPS present on the surface o f C. jejuni ATCC 81-176 and ATCC 81116 has

been shown to be involved in virulence (12, 13). To determine whether the modified
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heptose in the GPS o f ATCC 700819 plays a role in virulence as well, we identified three
genes, cj1427c, cjl428c and cj1430c that are putatively involved in modified heptose
biosynthesis, and have shown their involvement in CPS synthesis via an antibiotic
insertion knockout strategy. Using purified capsular samples and analysis via SDS-PAGE,
it was revealed that all the mutants showed a differential mobility o f the capsular bands
when compared to wild type, suggesting that the enzyme products o f the targeted genes
affected capsular composition.
The cjl427::C AT, cj!428::CAT and cjl427::CATA mutants displayed similar
capsular staining patterns when compared to each other (Figure 6A, B). Interestingly, the
cj!427::CAT and cjl428::CAT mutants showed a different modality o f CPS compared to
the wild type strain. A wide range o f both lower and high molecular weight species were
observed in these two mutants, indicating that the disruption o f these genes results in
changes in chain elongation o f the CPS.
In the cjl430::CAT mutant, the pattern obtained was significantly different from
that o f the other mutants, suggesting that the composition o f this mutant’s CPS was
different from the other mutants. This is puzzling, as both Cj 1428c and Cj 1430c are
thought to be putative epimerases. These two enzymes epimerize different carbons of the
heptose, so it may be possible that the different actions of these enzymes would be
reflected in the capsular staining pattern. However, the differences in staining pattern
cannot be due to differences in capsular structure, as NMR has shown that both the
cj!428::CAT and cj!430:\CAT mutants lack a heptose in their capsules. In addition to the
differential staining pattern o f the c jl430::CAT mutant, the amount o f CPS that is
produced by this mutant is significantly less than the other mutants that were investigated.
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It is possible that disruption o f this gene, and subsequently the enzyme that it encodes,
affects 'the transport o f CPS across the periplasmic space. This would cause an
accumulation o f CPS within the bacterium. As a result, this mutant behaves much like a
KpsM mutant, in that both are unable to transport CPS. Initial work in our laboratory has
shown that Cj 1430c is one o f the first enzymes to act in the heptose modification
pathway; its disruption could potentially have significant downstream effects leading to a
down regulation in the amount o f CPS that is produced.
Interestingly, the KpsM mutant also showed potential high molecular weight
species, suggestive o f CPS, despite the fact that this mutant lacks the KpsM
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transmembrane protein responsible for transport o f the CPS (20). It is known that the
KpsM mutant is acapsular (89), however, while transport o f the CPS across the
periplasmic space o f the bacterium is disrupted, CPS initiation and subsequent elongation
still occurs. These molecules o f assembled CPS, while not apparent on the cell surface of
C. jejuni, would be visualized during silver staining.

4.4

CPS purification for downstream analysis
Purification o f CPS is important, as one goal o f this purification is to perform

nuclear magnetic resonance (NMR) analysis so that its composition can be determined.
This analysis was able to give a glimpse o f the precise composition o f the capsule of the
wild type and mutant strains. More importantly, we can also determine the effects, if any,
o f disrupting the cj1427c, cj1428c and cj1430c genes on modified heptose synthesis.
However, a barrier to downstream analysis is that two molecules o f heptose also exist in
the LOS core o f C. jejuni (158). Thus, to remove LOS, purification o f CPS from wild
type, cjl427::CAT, cjl428::CAT, cjl430::CAT, KpsM and cjl427::CATA was attempted.
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Previous attempts in our laboratory (100) showed that the SDS solubilization
method was not effective at removing LOS from capsular preparations. As a result, the
hot water/phenol method outlined by Westphal and Jaan was used (171). Part o f this
method involves dialyzing phenol away from the aqueous phase after the hot
water/phenol purification. As the principle o f dialysis relies on simple diffusion, it was
thought that this extra step may have the added benefit o f allowing LOS to diffuse out o f
the sample. It was previously shown that LOS was significantly smaller than CPS (38),
and an appropriately sized dialysis tubing with a molecular weight cut off o f 12-14000
Daltons was chosen. With this cut off, molecules that are larger than 14000 Da, such as
CPS were retained within the tubing, while smaller molecules, such as LOS, would
diffuse out. To further remove LOS, the aqueous phase was then ultracentrifuged to pellet
LOS. It was determined that ultracentrifugation was important for the removal of LOS;
without this step, LOS contamination remained very high. Various durations were
attempted (12, 24, 30, 48 and 72 hours), with increasing amounts o f LOS being removed
with longer ultracentrifugation spins. However, after 30 hours, any additional LOS that
was removed was negligible. While this adapted hot water/phenol method worked well at
purifying CPS, a significant amount o f LOS still remained within the samples o f interest,
and additional purification was required.
The first purification method that was attempted after hot water/phenol
purification was size exclusion chromatography. In this method, components within a
given sample are separated based on their size, and hence the rate at which they move
through the gel matrix. The size o f LOS is significantly smaller than CPS (38), and
appropriate gel matrices capable o f resolving such small molecules were chosen. As CPS
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molecules are large, they w ill not be retained by the gel matrix, and will simply flow
through the column. However, based on results from silver staining, matrices that were
attempted failed to separate the LOS from the CPS. It was hypothesized that the LOS and
CPS were forming mixed micelles, resulting in the failure o f the gel matrix to separate
the LOS from the CPS. Micelles formed in this manner would have a gradient o f sizes
and separation via size exclusion chromatography would be impossible without their
disruption.
The first attempt to disrupt the mixed micelles was based on a method by Aspinall
et al (10), where LOS molecules are cleaved via an acetic acid treatment with heat.
Ideally, this method will cleave the linkage between the lipid A anchor and Kdo sugar,
resulting in smaller molecules that can then be retained by the gel matrix, while CPS
molecules will not be degraded, as they are heat stable (44,128). However, after samples
were separated via size exclusion chromatography, it was found that while the acetic acid
treatment was able to decrease the amount o f LOS to some extent, it had no effect on
separating LOS from CPS as fractions from size exclusion chromatography showed the
v

presence o f both CPS and LOS. It is possible that the LOS/CPS mixed micelles were
/
particularly resistant to acidic treatment, and were not easily separated. In addition, upon
removal o f the acid via ammonium bicarbonate neutralization, it is possible that the
micelles, initially disrupted by the acid treatment, reformed in a random manner.
As acetic acid treatment is quite harsh, and is conducted for a relatively long
duration o f time, it is conceivable that the CPS molecules may also be degraded. As a
result, in parallel, an ammonium acetate treatment was also attempted. Ammonium
acetate is also acidic, but much milder than acetic acid, and in principle, its action on
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LOS should be the same, while CPS should not be hydrolytically cleaved by this
treatment. The ammonium acetate treatment was thought to be successful at first, as LOS
molecules and CPS molecules appeared in different fractions. CPS molecules were not
retained by the gel matrix, and accordingly, appeared in early fractions. Contrasting this,
LOS molecules were well retained by the gel matrix, appearing in later fractions (Figure
7C). It was thought that this separation was due to the ammonium acetate treatment, and
to determine whether this was indeed the case, a tricine gradient gel was run (Figure 7D).
Due to the increasing percentage o f acrylamide at the bottom o f the gel, a gradient gel
will be able to resolve the differences in small molecules such as LOS. However, after
silver staining o f pooled fractions that contained LOS, it was observed that there was no
difference between the mock-treated and the ammonium acetate treated samples.
Therefore, it was concluded that this treatment had no effect on LOS molecules.
A final method o f purification that was attempted was based on the method
outlined by Gu and Tsai (53), where Nesseirial lipopolysaccharide was separated from
outer membrane vesicles via a sodium deoxycholate treatment. This method was adapted
for use in C. jejuni in an attempt to separate the LOS from the CPS molecules o f interest.
Sodium deoxycholate is a detergent, and should help to disrupt CPS/LOS mixed micelles.
However, upon size exclusion chromatography separation, it was found again that the
LOS co-eluted with the CPS, indicating that the sodium deoxycholate treatment failed to
disrupt the mixed micelles o f LOS and CPS. This may be due to the fact that the critical
micelle concentration for the mixed LOS/CPS species is quite low, resulting in micelles
that form easily while being difficult to disrupt with sodium deoxycholate. In the future,
it may be worth attempting a higher sodium deoxycholate concentration to disrupt the

micellar species. One unexpected effect o f the sodium deoxycholate treatment was that
the banding pattern o f GPS were much more readily observable via silver staining. The
reason for this increased resolution o f the banding pattern is unknown.
One caveat for all o f the purification methods attempted above is that they rely on
the assumption that once the LOS/CPS micelles are disrupted, the micelles will remain
disrupted. This is not necessarily the case, and one can envision that upon removal of the
disrupting agent, (acetic acid, ammonium acetate, sodium deoxycholate) the CPS and
LOS molecules will reform into micelles in a random fashion. To prevent the formation
o f these micelles, it may be necessary to reduce the concentration o f CPS and/or LOS to
levels below that o f the critical micelle concentration, with the caveat thatthis may make
downstream analyses very difficult due to the lower concentrations o f sample.
Due to the ineffectiveness o f multiple treatments that were attempted, CPS
samples which had only undergone the hot water/phenol extraction as well as
ultracentrifugation were sent directly for NMR structural analysis.

4.5

CPS composition of the mutants
Nuclear magnetic resonance (NMR) results from Dr. Knirel are summarized in

Table 1. This table consists o f two parts: data that was gathered via acid hydrolysis, and
information that was collected via NMR. In the main capsular backbone, one o f the three
constituent sugars is ribose; ideally, it should be stoichiometrically proportional to
galactosamine (GalN). The data in Table 1 showed that this was not the case. The
increase in ribose for all strains (with the exception o f cjl427::CATA) likely indicates
that some degree o f nucleic acid contamination is present, despite purification. For all
strains, small traces o f galactose were observed from acid hydrolysis. Acid hydrolysis is
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not able to cleave GalNAc to galactose, and thus, the presence o f galactose is likely from
traces o f contaminating LOS, as galactose is known to be a constituent (158). The amount
o f galactose that is present, however, shows that purification methods were sufficient to
significantly reduce the amount o f LOS present in samples. Unfortunately, other sugars
that are unique to LOS and not CPS, such as Kdo, could not be observed due to the harsh
nature o f the acid hydrolysis treatment. The presence o f Kdo should be minute in quantity,
showing that reduction o f LOS via purification was successful, resulting in only trace
amounts o f LOS present in the CPS enriched samples.
It was expected that the cj!427::CAT, cjl428::CAT and cjl430::CAT mutants
would lack a modified heptose; however, it was found that these mutants lack even an
unmodified heptose in their capsule. Based on silver stains showing the CPS o f these
mutants (Figure 6A, B), the cjl427\\C AT, cj!428::Q,AT and cjl427::CATA mutants
showed similar capsular staining patterns. However, for cj1430::CAT, the pattern
obtained was significantly different from that o f the other mutants, suggesting that the
composition o f this mutant’s CPS was different from the other mutants, contradicting
what was found via NMR. The differences observed in silver staining may suggest that
very subtle changes in the cell surface o f the mutants may be at play; this is expounded
by differences in chick colonization between the cjl428:\CAT and c/7730::CAT mutants
(100). While both were able to colonize chicks, c jl428::CAT had a much lower log
CFU/g o f cecum compared to the cj!430::CAT mutant (data not shown). The lack o f
heptose also supports the idea that LOS contamination was very low. The fact that no
heptose was detected indicates that the purification methods employed were successful at
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reducing the LOS to a level in which NMR results were not confounded by extraneous
heptoses from the LOS core.
As the mutants lack even a basic heptose as part o f their CPS, this reinforces the
notion that the glycosyltransferases responsible for transferring the sugar to the capsular
side-branch may be specific, particularly for a modified heptose. Without modification,
the transferases are unable to transfer the heptose to the capsule, and thus, will be absent
during analysis. Promiscuity o f the glycosyltransferases can be eliminated as NMR data
has shown that cjl428\\CAT and cj1430::CAT, both with disruptions in putative
epimerases o f heptose, lack heptose in the capsule, indicating that the correct sugar
epimer is required to facilitate its transfer. Importantly, despite the lack.of a heptose in
the CPS, a capsule is still produced, as shown in silver stains that have been conducted in
our lab (Figure 6A, B), which is similar to the findings that St. Michael et al (153) report
for a cj!428::CAT mutant.
Another observation from NMR results showed that the wild type strain contained
no phosphoramidate molecule. This is intriguing, as it is thought that the
phosphoramidate moiety is a normally occurring side-branch o f the ATCC 700819
capsule. However, McNally et al (114) report that it is possible that a hydroxyl group is
attached to the same location as the phosphoramidate moiety, so this may explain the
absence o f phosphoramidate in the wild type strain. The presence o f phosphoramidate on
the cjl427::CAT, cj!428::CAT and cj!430::CAT mutants is hypothesized to be due to a
compensatory mechanism o f the bacteria. As the capsular backbone is missing the
normally side-branching heptose, to compensate, the mutants attempt to make another
moiety that side-branches from the main capsular backbone, namely, phosphoramidate.

. 155
To verify this hypothesis, real-time PCR will be done in the future on the cluster o f genes
involved in phosphoramidate synthesis (cj1418c - cj 1415c) to determine whether
upregulation o f these genes is occurring.

4.6

The cjl427::CAT mutant grows better than wild type
Disruption o f the putative heptose modification genes o f interest, specifically

cj1427c, led to an increase in growth o f the mutant compared to the wild type strain. This
is puzzling, as it is normally thought that the wild type CPS would be conducive for
optimal growth. The lack o f a heptose for the c jl427::CAT mutant, as elucidated by
NMR, may indicate that there is a certain metabolic cost for maintaining the modified
heptose as part o f the CPS; once this is abolished via gene disruption, an increased
growth rate is observed. The other mutants also lack a heptose, and show an increase
growth rate compared to the wild type, lending credibility to this theory (100).
Interestingly, only a difference in initial growth rate was observed when the mutants were
grown in liquid media; when grown on plates, the mutants and wild type appear to grow
to approximately the same final density. The wild type and the mutants also grow to the
same final density in liquid media. This may indicate that while the cjl427:\CAT,
cjl428::CAT, c jl430::CAT and c jl427::CATA mutants have a faster initial growth rate,
they reach final levels o f density comparable to wild type.
Other phenotypic studies conducted for the heptoseless mutants also seem to
indicate that the role o f a modified heptose in C. jejuni interactions with host cells is
more complex than initially envisioned.
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4.7

Changes in the cjl427::CAT CPS plays a partial role in sensitivity to
: insult '
As C. jejuni is known to colonize the small intestine (178), one o f the first host

defenses encountered is bile. Bile is a digestive secretion that plays a major role in fat
dispersion and absorption. Bile acids, including cholates and deoxycholates, are
molecules that act like detergents and act as potent antimicrobials (15, 108); they are
secreted by the liver, stored and concentrated in the gall bladder and released into the
intestine. It is known that bile primarily exerts its effects on cell membranes, eventually
resulting in lysis o f potential pathogens. Enzyme assays have also confirmed leakage o f
intracellular material, implying that bile alters membrane integrity/permeability (45).
While information about bile tolerance o f Gram negative bacteria is relatively scarce, it is
believed that they are inherently more resistant to bile salts than Gram positive bacteria
(15, 22); this is why bile salts are often used in the selective enrichment o f Gram negative
bacteria (i.e. MacConkey agar). C. jejuni is considered bile resistant and has been isolated
from the gall bladder as well as directly from bile (48, 161). We sought to determine the
contribution o f alterations in CPS structure to C. jejuni bile resistance and tested a range
o f concentrations o f bile salts. The tested concentrations fall within physiological levels
o f bile salts that have been documented in the intestinal lumen (0.1 - 21 mM) (26). At
low bile salt concentrations, the wild type and the cj1427::CAT mutant showed resistance,
similar to the c jl428::CAT and cj!430::CAT mutants. However, at concentrations higher
than 0.5 g/L (approximately 1.2 mM), both strains showed the same susceptibility. This
contrasted the findings for the cjl428::CAT and cj1430::CAT mutants, which were more
susceptible to bile at these higher concentrations. As all mutants lack a heptose in their
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CPS, another factor, aside from the heptose, is playing a role in bile resistance. It is
known that bile salt resistance in C. jejuni is attributable to the CmeABC and CmeDEF
multidrug resistance pump (15, 105, 137). Inactivation o f the pump confers exquisite
sensitivity to bile salts (105). As disruption of cj1427c does not result in a change in these
efflux pump systems, it is not a surprise that the susceptibility pattern for the
cjl427::CAT mutant is unaltered compared to wild type. However, the increased
susceptibility in the cjl428::CAT and c jl430::CAT mutants remains to be elucidated.
In addition to bile salts, we also sought to determine whether the susceptibility of
C. jejuni was specific to bile salts, or whether changes in CPS composition also conferred
resistance to other types o f detergents. We chose sodium dodecyl sulfate (SDS) as it has
been shown that C. jejuni possesses resistance to this detergent (137). Exposing the
mutant to increasing concentrations o f SDS showed that there was no discemable effect
due to the lack o f a heptose in the CPS. This was reflected in the fact that both the wild
type and all our mutants showed similar levels o f susceptibility to SDS. The CmeDEF
multidrug efflux pump is responsible for resistance to SDS, and as the disruption of
cjl427c, cjl428c and cjl430c do not affect CmeDEF, it does not come as a surprise that
the susceptibility o f both the wild type and the mutants to SDS are similar. It is known
that the CPS is hydrophilic (13); the fact that our strains o f C. jejuni displayed similar
levels o f susceptibility to SDS likely indicates that the charged surface o f the bacteria has
not changed due to the absence o f a heptose in the CPS. To assay this, it would be
interesting to carry out a salt agglutination test (37,107, 147, 151). This method measures
cell surface hydrophobicity and net negative charge by agglutination in varying
concentrations o f ammonium sulfate. Agglutination in salt concentrations less than or
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equal to 1 M indicates a hydrophobic surface, whereas agglutination in high
concentrations o f salt (greater than or equal to 2 M) indicates a hydrophilic surface.
Once C. jejuni gains entry into the host intestine, it has the opportunity to gain
access to the vascular space and cause systemic infection (18). Amongst the multiple
innate immune defense mechanisms that are present in blood, complement is a key
component that can be found in serum. We thus sought to investigate whether alterations
in the CPS played a role in serum resistance. In contrast to the findings for detergents, we
found that, intriguingly, the cjl427::CAT mutant was killed nearly completely in the
presence o f low concentrations o f serum (20%), while the wild type strain showed only
60% death. In addition, timecourse experiments at this concentration o f serum showed
that the cjl427::CAT mutant was killed very quickly, within the first 15 minutes of
exposure to serum. This would seem to indicate that serum resistance is largely conveyed
by the presence o f heptose in the CPS and is critical for resistance; however, this is not
the case, as our other heptoseless mutants, cjl428::CAT and cjl430:\CAT do not show
the same pattern o f susceptibility to serum. While they are slightly more sensitive than
wild type, the same level o f extreme sensitivity as the c jl427::CAT mutant is not
observed, indicating that there is another factor at play.
It was previously thought that LOS does not play a role in serum resistance (13),
however, work by Guerry et al (56, 59) showed that a C. jejuni LOS mutant lacking distal
sialic acid residues is serum-sensitive, despite the presence o f CPS. Contrasting this, Keo
et al (89) found that in a systemic strain o f C. jejuni, LOS plays no role in serum
resistance. This may indicate that the composition and physical presentation o f unique
sugars on the surface o f C. jejuni, and perhaps more importantly, strain specificity, may
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play a role in conveying differing resistance against complement mediated killing. Based
on silver staining o f the capsule (Figure 6A, B), the cjl430::CAT mutant was shown to
have a different CPS staining pattern than the cjl428::CAT and cjl427::CAT mutants.
While CPS was being produced, the amount o f material was much less than the mutants,
indicating a potential defect in export of the complete capsular polysaccharide. In
addition, there are fewer bands compared to the wild type, indicating that fewer species
o f CPS with multiple sugar repeats are being produced. As changes in capsular
composition can alter the ability o f sugars to be silver stained (81, 158), it is possible that
mutations in cj1427c, cj1428c and cj1430c affect the CPS in different ways that results in
the variation seen for serum resistance. Alternatively, it may be that mutations in cjl427c,
cj1428c or cj1430c affect expression o f phosphoramidate related genes, leading to
varying levels o f phosphoramidate within the CPS o f each mutant, as previously
elucidated via NMR. The phosphoramidate moiety appears to be essential for serum
resistance, as the cjl427::CATA mutant (lacking both the phosphoramidate and heptose
moieties) that was previously investigated displayed extreme serum sensitivity. The
addition o f the phosphoramidate side-branch in the CPS'may be essential to prevent C3
complement deposition, and subsequent complement-mediated killing o f the bacteria.
It has been shown that CPS o f other bacterial species plays a role in modulating
the deposition o f the C3 complement component (166). It would be interesting to
determine whether C3 deposition on the surface o f our mutants is affected by the lack of
heptose.
Previous work done in our laboratory has shown that a capsuleless mutant o f C.
jejuni readily autoagglutinates over a period o f three hours (100). This was hypothesized
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that a lack o f CPS in C. jejuni exposes underlying adhesins, which are normally hidden
by the CPS. Our results indicated that the lack o f a heptose in the CPS did not play a role
in the autoagglutination o f bacteria, and that no underlying surface adhesins were
exposed.
As flagella and CPS are both anchored to the outer membrane o f C. jejuni, we
also sought to investigate whether changes in the CPS. would lead to changes in motility.
Interestingly, the cjl427::CAT mutant showed a significant decrease in motility
compared to the wild type, indicating that subtle:changes in the CPS may lead to
decreased motility. When comparing our other heptoseless mutants, it was found that all
mutants also showed significantly less motility than the wild type. As it has been shown
that the mutants all lack heptose in the CPS (see section 3.2.3), this suggests there may be
a link between the surface composition of C. jejuni and its motility. While there have
been no studies that link a heptoseless CPS and motility, the results in this thesis may
show that there are complex interactions between the genes involved in modified heptose
synthesis and the motility o f the organism.

4.8

The interactions of C. jejuni with Caco-2 intestinal cells and RAW 264.7
macrophages
Once C. jejuni has gained access to the host intestine, adhesion and subsequent

invasion o f intestinal epithelial cells is important for virulence. Based on our results, C.
jejuni ATCC 700819 was found to adhere to, and invade Caco-2 cells at a very low rate,
consistent with what has been previously reported in the literature (39, 47, 157). As no
differences were found between the wild type and the cj!427::CAT, cj!428::CAT and
cj!430::CAT mutant strains, this suggests that the absence o f a heptose on the CPS is
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unimportant for adhesion to Caco-2 cells. The cjl427::CATA mutant showed an increase
in adhesion (100); this may be due to the lack o f the phosphoramidate moiety. Its absence
from the CPS o f this mutant may allow increased adhesion due to the lack of steric
hindrance between adhesins and the host cells.
As the CFU counts for C. jejuni in the previous Caco-2 experiments were low, it
was hypothesized the CFUs were simply cell surface adherent bacteria that were able to
avoid killing by gentamicin. This could affect interpretation o f the results particularly
when investigating phagocytosis o f the bacteria into host cells. Via confocal microscopy,
verification that the bacteria were present intracellularly was conducted by Xuan Thanh
Bui. Preliminary results showed that the bacteria were indeed internalized*, validating our
gentamicin treatment to kill external bacteria in invasion assays.
Results for the adhesion, phagocytosis and survival o f C. jejuni within
macrophages showed that CPS structure, specifically the absence o f a heptose, does not
play a direct role in anti-phagocytosis, as the wild type and mutant strains were
phagocytosed by macrophages effectively.
In both infection and survival assays, the mutants showed slightly lower uptake
by and survival within macrophages, respectively. Our results for each strain are taken as
a CFU count in the presence o f macrophages over the CFU count in the absence of
macrophages. While the CFU counts for both the wild type and the mutants in the
presence o f macrophages were similar, in the absence of macrophages, the CFU counts
for the mutants were significantly higher (approximately 10 fold) compared to the wild
type strain, despite having the same initial multiplicity o f infection. Due to the higher
CFU counts, this may explain why infection and survival rates appear lower. This
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increase in growth is supported by the data in 3.3.1 and work previously done by our
laboratory where the mutants were found to grow more rapidly than the wild type (100).
It is possible that the low apparent rates o f the mutants are artifacts due to this increased
growth rate.
When investigating the phagocytosis o f the mutants compared to wild type, it was
observed that the mutants, showed more or less a steady state within macrophages. For
infection, it was expected that an increase in phagocytosis would be observed with an
increase in duration o f infection, as observed for wild type. As differences were observed,
this suggests that there may be either an inability o f the macrophages to phagocytose the
bacteria or a problem o f survival o f the mutants within macrophages. However, the latter
hypothesis was refuted when data for the survival within macrophages was analyzed; the
mutants were killed at approximately the same rate as the wild type, strain, indicating
there was no significant difference in the ability to survive within macrophages in all
strains.
As differences in phagocytosis, but not in survival were observed between the
wild type and mutant strains, we hypothesized that the differences observed were due to
changes in C. /eywwAnacrophage interactions that occurred at earlier timepoints.
Consequently, we dissected the adhesion of jC. jejuni to macrophages. The adhesion of
the mutants to macrophages showed no significant differences compared to wild type.
The slightly higher adhesion o f the KpsM mutant was previously hypothesized by our
laboratory to be due to the loss o f a capsule and the subsequent exposure o f underlying
adhesins (100). The slightly lower adhesion rate o f the cjl427::C AT A is puzzling; as it
lacks both heptose and phosphoramidate, there should be less steric hindrance for the
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underlying adhesins. As there were no defects for survival nor adhesion in the other
mutants, the reason for the differences observed in phagocytic rates is unclear at this time.
It is possible that the lack o f a heptose indirectly confers a fitness advantage. One
possibility for the decreased phagocytosis is due to a failure o f the macrophages to
activate. Macrophages are known to upregulate the production o f inflammatory cytokines
such as TNFa and IL-8 in the presence o f other Campylobacter species (110). However,
the caveat is that the production o f these proinflammatory cytokines is both
Campylobacter strain and species dependent. It is not unreasonable to consider that
changes in the surface properties o f C. jejuni will cause a defect in macrophage activation,
and subsequently, lead to less phagocytosis o f the bacteria. To test this possibility,
enzyme-linked immunosorbent assays (ELISA) can be used to determine whether the
macrophages are failing to activate (i.e. lack o f TNFa or IL-8 production) in the presence
o f the heptoseless mutants.
Rather than a failure o f the macrophages to activate, there is also the possibility
that the decreased phagocytosis o f the mutants is due to a pattern o f bacterial gene
expression that blocks further uptake o f the bacteria. If this is indeed the case, it will be
necessary to identify the genes that are differentially expressed between the mutants and
the wild type strains both inside and outside macrophages. To do this, a method known as
selective capture o f transcribed sequences (SCOTS) can be employed (33). In this
method, bacterial RNA can be isolated from infected macrophages, alleviating problems
due to abundant eukaryotic RNA in downstream analyses. The pool o f amplified
expressed bacterial genes can then be analyzed using DNA microarrays to determine
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whether differential gene expression plays in a role in conferring resistance against
uptake by macrophages.

4.9

Complementation of the C. jejuni mutants
Creation o f the complementation constructs was accomplished using the gene

splicing by overlap extension (gene SOE-ing) method. In this method, multiple fragments
are spliced together to generate the final complementation construct. The porA promoter
is a constitutively expressed promoter that drives the expression o f the complementation
construct at high levels, as previously shown (100). The kanamycin resistance cassette
was chosen so that complemented mutants could be selected. Once the complementation
constructs were successfully constructed and sequenced, they were inserted into a
pBluescript vector containing the 16S - 23 S rRNA regions, and then transformed into E.
coli. Great difficulty was encountered during attempts to transform E. coli with the
constructed vectors containing the gene SOEd products. Controls at each step of the
process (i.e. restriction digest o f plasmid, dephosphorylation o f the plasmid, T4 DNA
ligation, transformation efficiency, etc) were conducted in parallel to verify that each step
was occurring as envisioned. Upon acquiring data from the transformation efficiency
control, it was determined that even for the pBluescript plasmid (positive control), the
efficiency was very low per nanogram of DNA; the repeated inability to acquire
transformants containing the complementation constructs was likely due to this extremely
low transformation efficiency. However, despite these difficulties, the cj!427::CAT,
cjl428::CAT and cj!430\:CAT complementation constructs were transformed into E. coli
by another student in our laboratory, Xuan Thanh Bui. Once the complementation
constructs were transformed into E. coli, the plasmid was extracted in large quantities,
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and then verified via DNA sequencing to determine if mistakes in the sequence were
present.
Due to the nature o f gene SOE-ing, multiple PCRs must be conducted to make the
-final complementation construct. As a consequence o f PCR, single nucleotide
polymorphisms (SNPs) may be inadvertently introduced into the complementation
construct. This is likely due to the relatively low fidelity o f the DNA polymerase mix that
was chosen (Expand DNA Polymerase mix; a mix o f Taq DNA polymerase and Tgo
DNA polymerase). The cjl427::CAT complementation construct was found to contain
three SNPs, resulting in a glycine to aspartic acid change (G9D), a leucine to proline
change (L42P), and a serine to proline change (S142P). The G9D mutation results in the
disruption o f a Rossmann fold, a protein structural motif that binds cofactors such as
nicotinamide adenine dinucleotide (NAD) and is vital for folding and activity of the
enzyme (138). As this disruption would result in a non-fimctional protein, this SNP was
fixed via QuikChange mutagenesis PCR. For the L42P mutation, comparisons to ATCC
81-176 were done and it was found that the leucine was conserved, indicating that it was
likely important. Similar comparisons for the S142P also showed that it was conserved.
In addition, proline is known to be a disruptor in the middle o f regular secondary
structural elements, such as alpha helices and beta sheets (146). As o f final submission of
this thesis, all SNPs have been fixed, and the complementation construct has been
mobilized into the cjl427::CAT mutant. The c jl428::CAT complementation construct
was found to contain several SNPs. The first was a valine to alanine (V21A) mutation;
comparison to C. jejuni 81-176 revealed that a leucine was present, and thus, it was
decided that this amino acid was not very conserved. The second mutation resulted in a
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lysine to arginine (K100R) mutation. Comparison to C. jejuni 81-176 revealed that it also
possessed a leucine in this region; however, further comparisons to protein homologs
revealed that there was only a requirement for an amino acid with a polar NH2 group for
protein function. As a result, it was deemed that the SNPs were unlikely to affect the
function of the Cj 1428 protein. This complementation construct was used as is for our
phenotypic studies. Finally, the c jl430::CAT complementation construct was found to
contain no SNPs upon DNA sequencing.
With the successful completion of the QuikChange mutagenesis PCRs required to
remove the SNPs in the complementation construct, it, along with the c jl428::CAT and
c jl430::CAT complementation constructs were mobilized into their respective C. jejuni
mutants using the method outlined by Donahue et al (36). Mobilization of the
c jl428::CAT plasmid into the cjl428::CAT mutant was successful using both
electroporation and natural transformation. It was noted that natural transformation was
much more efficient than electroporation; this may be due to several factors. Firstly, it is
known that C. jejuni is naturally competent (178); this in combination with the fact that
the complementation construct has been selectively methylated to have the restriction
endonuclease signature o f C. jejuni ATCC 700819 results in highly efficient
transformation. Electroporation was also thought to be less efficient than natural
transformation due to the stress that is placed onto the cells during the procedure.
Regardless of the method that was used, transformants for the cjl428::CAT complement
were obtained. These potential clones were screened via PCR to ensure that the
complementation construct was indeed present within C. jejuni. While PCR showed that
the complementation construct was within C. jejuni, homologous recombination into the
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16S - 23S rRNA region of the genome did not occur (Figure 19A and B, respectively).
This is puzzling, as there are three copies of the 16S - 23 S rRNA region within the C.
jejuni genome (87); by design, the complementation construct should have integrated into
one of these three regions. Due to this failure to integrate into the 16S - 23 S rRNA region,
we attempted to investigate the precise location of the complementation construct. The
other two elements in the complementation construct were the cj1428c gene and the porA
promoter. Each gene was investigated using flanking primers to determine whether the
complementation construct inadvertently recombined into these areas as homologous
recombination can occur with as few as 200-300 base pairs (3, 80). PCR revealed no
increase in size corresponding to the insertion of the complementation construct in either
gene (Figure 19C and D, respectively). It was also verified that the pBluescript vector
was not replicating within C. jejuni by attempting to extract the plasmid. The failure to do
so agrees with the literature that indicates the pBluescript vector is a suicide vector.
While the complementation construct did not integrate into the 16S - 23 S rRNA region
as initially desired, the construct has been verified to be within C. jejuni, and thus,
phenotypic studies involving this complemented mutant were conducted.
Interestingly, for the cjl430::CAT mutant, both electroporation and natural
transformation were not successful at transforming the complementation plasmid into G.
jejuni, despite it being methylated. At first, it was thought that the surface properties of
the cjl430::CAT mutant were refractive to transformation. This would result in an
inability o f the plasmid to enter the cells. However, this theory was quickly disproved
when it was found that the cjl430::CAT complementation plasmid was unable to enter
the easily transformable cj!428::CAT mutant as well. In addition, the cjl428\\CAT
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complementation construct as well as other plasmids in our collection were easily
transformed into the cjl430::CAT mutant, indicating that the problem was not due to
differences in the surface properties of the cjl430::CAT mutant. The reason for the
inability o f the cj!430::CAT complementation construct to be mobilized into the
cjl430::CAT mutant is unknown at this time. One possible explanation for this failure is
that Cjl430c may require another interacting protein within the capsular cluster to be
expressed at wild type levels. However, preliminary data in our laboratory by M.
McCallum indicates Cj 1430c does not interact with any of the other enzymes within the
capsular cluster. In the future, to complement the cj1430::CAT mutant, a cjl426c cj1430c complementation construct may be attempted. While the construction and
subsequent transformation of this construct will be difficult due to the large size (> 8 Kb),
it may alleviate the difficulties encountered when attempting to complement the
c jl430::CAT mutant. The region from cjl426c - cjl430c will be used so that the
expression of each gene product is at equimolar level; this will also ensure that if (an)
interacting partner(s) is (are) required by any of the enzymes within the capsular cluster,
this requirement will be met. A shuttle plasmid based complementation approach will be
used if this method is attempted, for several reasons. Firstly, homologous recombination
into the 16S - 23 S rRNA region was shown not to work for the complemented
cjl428::CAT mutant. Secondly, with a large region of the C. jejuni genome in the
plasmid, there is a high chance that inadvertent homologous recombination will occur,
causing additional problems.
Despite the failure of the c jl428::CAT complementation construct to integrate
into the desired area o f interest, the phenotypes that were previously investigated by our
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laboratory (100) and showed striking differences compared to the wild type were
analyzed in the complemented strain to determine whether the phenotypes would be
restored to wild type levels. Specifically, complementation should restore the
susceptibility of the mutant to be phagocytosed by macrophages, restore the survival
kinetics of the mutant within macrophages to wild type susceptible levels and return
motility to wild type levels.
When the survival within macrophages of the complemented cjl428:\CAT mutant
was investigated, it was found that complementation occurred (Figure 22). Interestingly,
the complemented cjl428::CAT mutant is able to survive better within macrophages; this
may be due to the overexpression of Cj 1428c, as production of this enzyme is driven by a
highly active par A promoter.
The phagocytosis o f the complemented c jl428:: CAT mutant was partially
complemented to wild type levels (Figure 23), particularly at timepoint one. However, at
later timepoints, complementation does not seem to be occurring. This indicates that
partial complementation for the initial steps of infection (i.e. adhesion and initial
internalization) is likely occurring. As the data from (Figure 22) shows that
complementation is occurring, this indicates that there may be differences on the surface
of the complemented cj!428:\C AT mutant that results in the blockage o f further
internalization. While the c jl428::CAT complementation construct did not integrate into
the desired 16S - 23 S rRNA area, complementation is occurring due to the expression of
Cj 1428c (Figure 20).
It was found that motility of the cjl428::CAT mutant was significantly reduced
compared to wild type (Table 3). Contrary to expectations, results showed that the
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complemented mutant was less motile than both the wild type and the cjl428::CAT
mutant. The decrease in motility was deemed significant (p < 0.05) when comparing the
diameter o f the halos to the wild type and also to the cj!428:: CAT mutant.
The failure o f the complementation construct to restore motility, while
complementing the macrophage phenotypes that were studied cannot be explained at this
time. It is possible that the complementation construct is somehow affecting genes
involved in motility of C. jejuni. Further elucidation will need to be conducted to
determine where the construct has integrated. This can be accomplished using inverse
PCR after digestion o f the C. jejuni genome with a low - medium frequency restriction
endonuclease to create multiple fragments. As the construct must not be cut by the
restriction endonuclease for this strategy to work, this necessitates a relatively uncommon
restriction endonuclease. The fragments can then be ligated together to create circularized
DNA, and inverse PCR carried out to generate PCR products that can then be sequenced
to determine the precise integration site o f the cj!428:: CAT complementation construct.

4.10

Overall summary
C. jejuni is a pathogen that is able to cause disease in humans, and it has evolved

to successfully achieve this goal. The work that has been carried out as part of this thesis
has furthered our knowledge of the involvement of modified heptoses in the C. jejuni
capsule in pathogenesis. Once ingested, C. jejuni must avoid the bile that is secreted by
the gall bladder, and then adhere to and invade the target intestinal epithelial cells.
Following this, the bacterium must evade avoid host defense such as complement and
macrophages. With the disruption of putative genes involved in modified heptose
production, we had in our possession the exclusively heptoseless cj!428::CAT, and
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c jl430::CAT mutants, the capsuleless KpsM mutant and the side-branchless
cjl427::CATA mutant. Since then, we have also completed the heptoseless cjl427::CAT
mutant.
Nuclear magnetic resonance (NMR) has elucidated the composition of the capsule
in each of these mutants, and revealed that the cjl427::CAT,cjl428"CAT, cjl430:\CAT,
and cjl427::CATA mutants all lack heptose. With exception of the cjl427::CATA mutant,
the c jl427::CAT, cjl428::CAT, cjl430::CAT also showed the confirmed presence of
phosphoramidate, while the wild type strain did not. This likely indicates that capsular
phase variability is occurring. This phase variability may assist C. jejuni in the evasion
of host defenses.
Real-time PCR was initially conducted to verify that the insertion of the
chloramphenicol antibiotic resistance cassette into the mutants was non-polar. However,
it was also found that the levels of some of the genes investigated within the capsular
cluster showed very low levels o f expression. This could either be due to the differential
degradation o f the mRNA or could be attributed to the actual low expression levels of the
genes. Therefore, complementation was still necessary to assess gene specificity of the
phenotypes.
Interestingly, the newly constructed cjl427\:C AT mutant showed different
phenotypes compared to the cjl428:\C AT and cjl 43 O:\CAT mutants, despite all o f these
mutants lacking a heptose and having similar capsular compositions. The cjl427:\C AT
mutant was found to be significantly susceptible to serum, while comparatively resistant
to bile salts. In addition, the cjl427\\<2AT mutant was found to be phagocytosed by
macrophages as much as wild type, and showed similar survival kinetics within
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macrophages, again differing from the observed trends for the c jl428::CAT and
cjl430::CAT mutants. This indicates that the modified heptose is not directly responsible
for changes in the pathogenesis of C. jejuni, and that another factor is at play.
While complementation of the cj!427::CAT and c jl430::CAT mutants has yet to
be completed, thus far, the cjl428::CAT mutant has been complemented, despite the
complementation construct not recombining into the desired 16S - 23 S rRNA region.
While restoration o f motility o f the mutant was not observed, restoration o f the
phagocytosis rate as well as survival kinetics to wild type susceptible levels was observed
indicating that the phenotypes observed for the cjl428::C AT mutant were gene specific.

4.11

Future Directions
The real-time PCR data that have been gathered as part of this thesis has raised

several interesting questions. Further work is warranted to determine whether the low
levels o f transcript found by real-time PCR represent actual changes in gene expression.
This can be accomplished using a reporter system to determine whether regulatory effects
are causing the lowered expression levels observed. In addition, investigation into
phosphoramidate synthetic genes will allow us to determine why the wild type lacks a
phosphoramidate, while the cjl427::CAT, cjl428::CAT, and cjl430::CAT mutants
possess a phosphoramidate. Upregulation o f genes involved in phosphoramidate as a
compensatory mechanism for the lack o f heptose may be responsible, and thus
determination if these genes are being more highly expressed is needed.
The different trends for the cjl427::CAT mutant that were observed in the
phagocytic uptake as well as survival within macrophages experiments have also raised
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several interesting questions. As the cjl427::CAT, cjl428::CAT, and cjl430::CAT
mutants all have the same capsular composition as elucidated by NMR, it was expected
that they would behave similarly. However, this was not the case, as the c jl42 7::CAT
mutant behaved like the wild type, while the cjl428::CAT and cjl430::CAT mutants did
not. Enzyme-linked immunosorbent assays (ELISA) will determine if the macrophages
are failing to activate in the presence of these different mutants. Alternatively, using
selective capture o f transcribed sequences (SCOTS), it will be possible to determine
genes that may be differentially expressed within each mutant and the wild type both
inside and outside the macrophage. This will also aid in the understanding of bacterial
factors necessary for prolonged survival of C. jejuni within macrophages. ,
Lastly, the work that has been presented as part of this thesis has shown that the
role of the modified heptose in the C. jejuni CPS is not as straightforward as initially
imagined. While the work presented here has shed light on some important aspects of C.
jejuni pathogenesis, more importantly, it has laid the groundwork for future studies in the
field. Elucidation o f the various factors involved in C. jejuni pathogenesis and
identification of novel targets for therapeutic agents against C. jejuni will help alleviate
the symptoms caused by this organism and possibly eliminate this pathogen from the
world.

APPENDICES
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Vectors
pHcl 3

p R Y lll

pET23 cj1427:: CAT
pBluescriptKS(+):: 16SrRNA28SrRNA

pBluescriptKS(+)::16SrRNA28SrRNA (-Xbal)

H. pylori shuttle vector
containing
a
kanamycin
resistance cassette
C. jejuni shuttle vector
containing a chloramphenicol
resistance cassette
The CAT cassette (743 bp)
inserted into cjl427
The
16SrRNA-28SrRNA
intragenic region (1400 bp)
inserted
into
pBluescriptKS(+)
The
16SrRNA-28SrRNA
intragenic region (1400 bp)
inserted
into
pBluescriptKS(+) with the
additional Xbal site in
pBluescriptKS being removed

Heuermann and Haas,
1998
Yao e t a l , 1993

This study
This study

This study

Primers

Sequence (5’ - 3 ’)

Aph3 PI

eaasatctsataaacccagcgaacca

Aph3 P2

agestccategaeacatctaaatctaggtac

CatColi P2

gtcggta ccttatttattcagcaagtcttg

CatColi P3

gtcatcgggcccttcctttccaagttaattgc

cjl418 PI

cactcttactgcttccatctg

cjl421 PI

ggtcaaactgtgatagaacatag

cjl421 P2

ccccattttctaccataagc

cjl421 P3

gctactatatctggacgatg

cjl421 P4

;

gattgcggcctttgtccttc

cjl422 P2

ggctgaatttgggttgagcatgg

cjl422 P3

ggatatagttggagacaagac
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cjl422 P4

gaattggtataaaggaggtgg

cjl423 PI

gatattggtgtgcctgagg

cj!427?3

scetcesatccttaattaaaatttecaaagcea

c/1427 P4

etgggtacctagaatgagacttga

cjl427 P5

ctgctagggcccatattctgagatagg

cjl428 P2

aggtaccatgggcatgcaaacaaattcaaaaatataa

cjl428 P3

gctsgatcctcaattttgtgttttatacca

cj!428 P4

gtgeetacctgtagctatctatacgatgc

cj1428 P5

ctgctaeeecccctcaggatacatataccca

c/1430 P2

agggtccatsecaatagaatttgatata

cjl430 P3

gcgtcggatccttatcctttatttttagttgcaa

cjl430 P4

gtgggtaccaaatatgggaaattct

c/l 430 P5

ctgctagggcccattttaaataggttgg

P2

aggtaccatggtgagttatgattatagtttatg

kpsM~P3

gctggatcctagattaattaactttatcattc

kpsMY4

gaagatcttgtatttcctgttcatttgc

kpsM P6

aggtaccatggagttctagcaataaatacatg

Complementation primers
KAN 1427 Rev

caaatggttcgctgggtttcttaattaaaatttgcaaagcgatta

KAN For 1427

taatcgctttgcaaattttaattaagaaacccagcgaaccatttg

KAN 1428 Rev

tcaaatggttcgctgggtttctcaattttgtgttttataccattc

KAN For 1428

gaatggtataaaacacaaaattgagaaacccagcgaaccatttga
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KAN 1430 Rev

caaatggttcgctgggtttcttatcctttatttttagttgcaag

KAN For 1430

cttgcaactaaaaataaaggataagaaacccagcgaaccatttg

kpsM Rev CAT

gcaattaacttggaaaggaactcattctttttttaccgccgtt

CAT For kpsM

aacggcggtaaaaaaagaatgagttcctttccaagttaattgcg

16S rRNAIGS Top

ctggaactcaactgacgctaa

28S rRNA IGS Bottom

ctcttgcacattgcagtccta

OmpE prom Fwd IGS

ggttggatcacctcctttctctttagatgtttttatccttcgg

OmpE-for-Xbal

ectctaeactttaeatetttttatccttc

IGS Rev ompE Prom

ccgaaggataaaaacatctaaagagaaaggaggtgatccaacc

28S rRNA Fwd KAN

ttagtacctagatttagatgtcaaaagtaataagtctcacaactatt

Aph3P3

gctctagagacatctaaatctaggtac

28S rRNA Fwd CAT

gaggaaggaaataataaatggctaaagtaataagtctcacaactatt

CAT-reverse-Xbal

gctctagagccatttattatttccttcctc

KAN rev 28S rRNA

aatagttgtgagacttattacttttgacatctaaatctaggtactaa

CAT rev 28SrRNA

aatagttgtgagacttattactttagccatttattatttccttcctc

1427 For ompE

taatttttgacaaggagaattctcatgtcaaaaaaagttttaattacag

1428 Fwd ompE

taatttttgacaaggagaattctcatgcaaacaaattcaaaaatatatata

1430 Fwd ompE

taatttttgacaaggagaattctcatggcaatagaatttgatatacaa

KpsM Fwd ompE

taatttttgacaaggagaattctcatgttaaatgtaatttatgctttattt

ompE pro Rev 1427

ctgtaattaaaactttttttgacatgagaattctccttgtcaaaaatta

ompE Pro Rev 1428

tatatatatttttgaatttgtttgcatgagaattctccttgtcaaaaatta

ompE pro Rev 1430

ttgtatatcaaattctattgccatgagaattctccttgtcaaaaatta

ompE prom Rev kpsM

aaataaagcataaattacatttaacatgagaattctccttgtcaaaaatta

16S rRNA Top Primer - Kpnl

seeetacccteeaactcaacteacectaa

28S rRNA Bottom Primer - BamHI

ceffgatccctcttecacattecastccta

23 S rRNA Bottom Notl

ataaeaatscssccsctcttecacattecaetccta

Real-time PCR primers
1425 RTBtm

accacttggtacatccgaataggt

1425 RT Top

tgcgactatatctttatacatacattg

1426 RTBtm

ttatcgacataaagcatcttgtaaaaaa

1426 RT Top

attgataatcatcagcaagctaggaa

1427 RTBtm

ccgcatgcactttatcgatccca

1427 RT Top

ctgatattattattcctctagctgct

1428 RT Top

caagcggttgctaaattttttaaagaa

1428 RT Btm

aaatcaccttgaaataaatattcctctt

1429 RTBtm

gcttgtaccaaagtaattgtattctc

1429 RT Top

gaataggtggtaatggagatggtg

1430 RT Top

cagatggaattaaatttaag'catgaca

1430 RTBtm

tggtggtaataaaataagttgctgatt

Acetyl RTBtm

tagccccaatccttgcacaagct

Acetyl RT Top

aatgtcttgatcgtcatatgaaaacaa

Cj 1444 RT Top

agtggtggattctcaaggaaatattt

Cj 1444 RTBtm

tgaatccgaactaagtccttgataaa

Cj 1445 RTBtm

aaggtaaatctatatgttgctcttgat

Cjl445 RT top

atacattgattgcagcaccaagatat

v

RTCj 1447c Fwd

cctttatttagtggtggaagacatta

RTCj 1447c Rev

ttatctctagctgttaaagaaccttg

KpsMRTBtm

attacaaaataaatacaaaactcaagtaa

KpsM RT Top

gttagagaatatcatcatcaagttatg
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